UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September
30, 2023
OR
☐ TRANSITION REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to
______
Commission File No.
001-41177
NORTHVIEW ACQUISITION CORP.
(Exact name of registrant as specified in its
charter)
Delaware | | 86-3437271 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) |
207 West 25th St., 9th Floor New York, NY | | 10001 |
(Address of principal executive offices) | | (Zip Code) |
(212) 494-9022
(Registrant’s telephone number, including
area code)
N/A
(Former name, former address and former fiscal
year, if changed since last report)
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Common Stock, $0.0001 par value per share | | NVAC | | The Nasdaq Stock Market LLC |
Rights, each right convertible into one-tenth of one share of common stock | | NVACR | | The Nasdaq Stock Market LLC |
Warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per whole share | | NVACW | | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ |
Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| | Emerging growth company | ☒ |
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☒ No ☐
As of November 20, 2023, there were 6,167,882 shares
of common stock, $0.0001 par value outstanding.
NORTHVIEW ACQUISITION CORP.
FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2023
TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements.
NORTHVIEW ACQUISITION CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
| |
September 30,
2023 (Unaudited) | | |
December 31, 2022 | |
Assets | |
| | |
| |
Current Assets: | |
| | |
| |
Cash | |
$ | 17,342 | | |
$ | 193,486 | |
Prepaid expenses and other current assets | |
| 135,625 | | |
| 318,218 | |
Total Current Assets | |
| 152,967 | | |
| 511,704 | |
| |
| | | |
| | |
Cash and marketable securities held in Trust Account | |
| 10,651,566 | | |
| 194,224,782 | |
Total Assets | |
$ | 10,804,533 | | |
$ | 194,736,486 | |
| |
| | | |
| | |
Liabilities, Redeemable Common Stock and Stockholders’ Deficit | |
| | | |
| | |
Current Liabilities: | |
| | | |
| | |
Accrued expenses | |
$ | 437,042 | | |
$ | 448,480 | |
Excise tax payable | |
| 1,848,455 | | |
| — | |
Income tax payable | |
| 57,434 | | |
| 462,271 | |
Convertible promissory note | |
| 601,239 | | |
| — | |
Due to related party | |
| 55,000 | | |
| 25,000 | |
Total Current Liabilities | |
| 2,999,170 | | |
| 935,751 | |
| |
| | | |
| | |
Deferred tax liability | |
| — | | |
| 36,940 | |
Warrant liabilities | |
| 667,708 | | |
| 857,787 | |
Total Liabilities | |
| 3,666,878 | | |
| 1,830,478 | |
| |
| | | |
| | |
Commitments and Contingencies | |
| | | |
| | |
Common stock subject to possible redemption, 974,132 and 18,975,000 shares at redemption value of approximately $10.90 and $10.20 at September 30, 2023 and December 31, 2022, respectively | |
| 10,620,981 | | |
| 193,525,484 | |
| |
| | | |
| | |
Stockholders’ Deficit: | |
| | | |
| | |
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding | |
| — | | |
| — | |
Common stock, $0.0001 par value; 100,000,000 shares authorized; 5,193,750 shares issued and outstanding at September 30, 2023 and December 31, 2022 (excluding 974,132 and 18,975,000 shares subject to possible redemption at September 30, 2023 and December 31, 2022, respectively) | |
| 519 | | |
| 519 | |
Accumulated deficit | |
| (3,483,845 | ) | |
| (619,995 | ) |
Total Stockholders’ Deficit | |
| (3,483,326 | ) | |
| (619,476 | ) |
Total Liabilities, Redeemable Common Stock and Stockholders’ Deficit | |
$ | 10,804,533 | | |
$ | 194,736,486 | |
The accompanying notes are an integral part of
the unaudited condensed consolidated financial statements.
NORTHVIEW ACQUISITION CORPORATION
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS
| |
For the Three Months Ended September 30, | | |
For the Nine Months Ended
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Formation and operating costs | |
$ | 290,098 | | |
$ | 404,425 | | |
$ | 1,048,525 | | |
$ | 863,546 | |
Loss from operations | |
| (290,098 | ) | |
| (404,425 | ) | |
| (1,048,525 | ) | |
| (863,546 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other income (expense): | |
| | | |
| | | |
| | | |
| | |
Interest income earned on cash and marketable securities held in Trust Account | |
| 138,725 | | |
| 1,136,826 | | |
| 2,103,111 | | |
| 1,371,326 | |
Change in fair value of convertible loan | |
| 53,186 | | |
| — | | |
| 111,776 | | |
| — | |
Change in fair value of warrant liabilities | |
| (243,659 | ) | |
| 1,074,374 | | |
| 190,079 | | |
| 6,246,897 | |
Total other (expense) income, net | |
| (51,748 | ) | |
| 2,211,200 | | |
| 2,404,966 | | |
| 7,618,223 | |
| |
| | | |
| | | |
| | | |
| | |
(Loss) income before provision for income tax | |
| (341,846 | ) | |
| 1,806,775 | | |
| 1,356,441 | | |
| 6,754,677 | |
Income tax provision | |
| (25,499 | ) | |
| (42,962 | ) | |
| (430,502 | ) | |
| (69,484 | ) |
Net (loss) income | |
$ | (367,345 | ) | |
$ | 1,763,813 | | |
$ | 925,939 | | |
$ | 6,685,193 | |
| |
| | | |
| | | |
| | | |
| | |
Basic and diluted weighted average shares outstanding, common stock subject to possible redemption | |
| 974,132 | | |
| 18,975,000 | | |
| 6,183,174 | | |
| 18,975,000 | |
Basic and diluted net (loss) income per share, common stock subject to possible redemption | |
$ | (0.06 | ) | |
$ | 0.07 | | |
$ | 0.08 | | |
$ | 0.28 | |
Basic and diluted weighted average shares outstanding, common stock | |
| 5,193,750 | | |
| 5,193,750 | | |
| 5,193,750 | | |
| 5,193,750 | |
Basic and diluted net (loss) income per share, common stock | |
$ | (0.06 | ) | |
$ | 0.07 | | |
$ | 0.08 | | |
$ | 0.28 | |
The accompanying notes are an integral part of
the unaudited condensed consolidated financial statements.
NORTHVIEW ACQUISITION CORPORATION
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF CHANGES IN STOCKHOLDERS’ DEFICIT
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER
30, 2023
| |
Common stock | | |
Additional Paid-In | | |
Accumulated | | |
Total Stockholders’ | |
| |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Deficit | |
| |
| | |
| | |
| | |
| | |
| |
Balance as of December 31, 2022 | |
| 5,193,750 | | |
$ | 519 | | |
$ | — | | |
$ | (619,995 | ) | |
$ | (619,476 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Accretion of common stock to redemption value | |
| — | | |
| — | | |
| — | | |
| (1,279,617 | ) | |
| (1,279,617 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Excise tax on stock redemptions | |
| — | | |
| — | | |
| — | | |
| (1,848,455 | ) | |
| (1,848,455 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Net income | |
| — | | |
| — | | |
| — | | |
| 440,895 | | |
| 440,895 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance as of March 31, 2023 (unaudited) | |
| 5,193,750 | | |
| 519 | | |
| — | | |
| (3,307,172 | ) | |
| (3,306,653 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Accretion of common stock to redemption value | |
| — | | |
| — | | |
| — | | |
| (419,670 | ) | |
| (419,670 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Net income | |
| — | | |
| — | | |
| — | | |
| 852,389 | | |
| 852,389 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance as of June 30, 2023 (unaudited) | |
| 5,193,750 | | |
| 519 | | |
| — | | |
| (2,874,453 | ) | |
| (2,873,934 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Accretion of common stock to redemption value | |
| — | | |
| — | | |
| — | | |
| (242,047 | ) | |
| (242,047 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Net loss | |
| — | | |
| — | | |
| — | | |
| (367,345 | ) | |
| (367,345 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance as of September 30, 2023 (unaudited) | |
| 5,193,750 | | |
$ | 519 | | |
$ | — | | |
$ | (3,483,845 | ) | |
$ | (3,483,326 | ) |
FOR THE THREE
AND NINE MONTHS ENDED SEPTEMBER 30, 2022
| |
Common stock | | |
Additional Paid-In | | |
Accumulated | | |
Total Stockholders’ | |
| |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Deficit | |
| |
| | |
| | |
| | |
| | |
| |
Balance as of December 31, 2021 | |
| 5,193,750 | | |
$ | 519 | | |
$ | — | | |
$ | (5,909,749 | ) | |
$ | (5,909,230 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Net income | |
| — | | |
| — | | |
| — | | |
| 3,709,017 | | |
| 3,709,017 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance as of March 31, 2022 (unaudited) | |
| 5,193,750 | | |
| 519 | | |
| — | | |
| (2,200,732 | ) | |
| (2,200,213 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Accretion of common stock to redemption value | |
| — | | |
| — | | |
| — | | |
| (132,478 | ) | |
| (132,478 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Net income | |
| — | | |
| — | | |
| — | | |
| 1,212,363 | | |
| 1,212,363 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance as of June 30, 2022 (unaudited) | |
| 5,193,750 | | |
| 519 | | |
| — | | |
| (1,120,847 | ) | |
| (1,120,328 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Accretion of common stock to redemption value | |
| — | | |
| — | | |
| — | | |
| (1,017,341 | ) | |
| (1,017,341 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Net income | |
| — | | |
| — | | |
| — | | |
| 1,763,813 | | |
| 1,763,813 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance as of September 30, 2022 (unaudited) | |
| 5,193,750 | | |
$ | 519 | | |
$ | — | | |
$ | (374,375 | ) | |
$ | (373,856 | ) |
The accompanying notes are an integral part of
the unaudited condensed consolidated financial statements.
NORTHVIEW ACQUISITION CORPORATION
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF CASH FLOWS
| |
For the Nine Months Ended
September 30, | |
| |
2023 | | |
2022 | |
Cash flows from operating activities: | |
| | |
| |
Net income | |
$ | 925,939 | | |
$ | 6,685,193 | |
Adjustments to reconcile net income to net cash used in operating activities: | |
| | | |
| | |
Interest income on cash and marketable securities held in Trust Account | |
| (2,103,111 | ) | |
| (1,371,326 | ) |
Change in fair value of convertible note | |
| (111,776 | ) | |
| — | |
Change in fair value of warrant liabilities | |
| (190,079 | ) | |
| (6,246,897 | ) |
Changes in operating assets and liabilities: | |
| | | |
| | |
Prepaid expenses and other current assets | |
| 182,592 | | |
| 237,418 | |
Accrued offering costs and expenses | |
| (11,438 | ) | |
| 215,900 | |
Income tax payable | |
| (404,837 | ) | |
| 69,484 | |
Due to related party | |
| 30,000 | | |
| 8,387 | |
Deferred tax liability | |
| (36,940 | ) | |
| — | |
Net cash used in operating activities | |
| (1,719,650 | ) | |
| (401,841 | ) |
| |
| | | |
| | |
Cash flows from investing activities: | |
| | | |
| | |
Payment of extension fee into Trust Account | |
| (340,947 | ) | |
| — | |
Cash withdrawn from Trust Account in connection with redemption | |
| 184,845,836 | | |
| — | |
Reimbursement by related party | |
| — | | |
| 25,000 | |
Reimbursement of franchise and income taxes from Trust Account | |
| 1,171,438 | | |
| 8,484 | |
Net cash provided by investing activities | |
| 185,676,327 | | |
| 33,484 | |
| |
| | | |
| | |
Cash flows from financing activities: | |
| | | |
| | |
Proceeds from convertible promissory note | |
| 713,015 | | |
| — | |
Redemption of common stock | |
| (184,845,836 | ) | |
| — | |
Net cash used in financing activities | |
| (184,132,821 | ) | |
| — | |
| |
| | | |
| | |
Net change in cash | |
| (176,144 | ) | |
| (368,357 | ) |
Cash, beginning of the period | |
| 193,486 | | |
| 741,228 | |
Cash, end of the period | |
$ | 17,342 | | |
$ | 372,871 | |
Supplemental disclosure of cash flow information: | |
| | | |
| | |
Income taxes paid, inclusive of interest and penalties | |
$ | 891,437 | | |
$ | — | |
Excise tax payable attributable to redemption of common stock | |
$ | 1,848,455 | | |
$ | — | |
Accretion of common stock to redemption value | |
$ | 1,941,334 | | |
$ | 1,149,819 | |
The accompanying notes are an integral part of
the unaudited condensed consolidated financial statements.
NORTHVIEW ACQUISITION CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
Note 1 – Description of Organization and Business Operations
NorthView Acquisition Corporation (the “Company”
or “Northview”) is a blank check company incorporated in Delaware on April 19, 2021. The Company was formed for the purpose
of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with
one or more businesses (“Business Combination”). The Company has not selected any specific Business Combination target. While
the Company may pursue an initial Business Combination target in any business, industry or geographical location, it intends to focus
its search on businesses that are focused on healthcare innovation.
The Company has a wholly-owned subsidiary, NV
Profusa Merger Sub Inc. (“Merger Sub”), a Delaware corporation incorporated on October 13, 2022, formed solely in contemplation
of the Merger with Profusa (See Note 6). Merger Sub has not commenced any operations and has only nominal assets and no liabilities or
contingent liabilities, nor any outstanding commitments other than in connection with the Merger.
On December 22, 2021, the Company consummated
its Initial Public Offering (“IPO”) of 18,975,000 units (the “Units”), which included 2,475,000 Units issued
pursuant to the full exercise of the over-allotment option granted to the underwriters. Each Unit consists of one share of common stock
of the Company, par value $0.0001 per share, one right (the “Rights”), and one-half of one redeemable warrant of the Company
(the “Warrants”). Each Right entitles the holder thereof to receive one-tenth (1/10) of one share of common stock. Each Warrant
entitles the holder thereof to purchase one share of common stock for $11.50 per share, subject to adjustment. The Units were sold at
a price of $10.00 per Unit, generating gross proceeds to the Company of $189,750,000.
Simultaneously with the closing of the IPO, the
Company completed the private sale of an aggregate of 7,347,500 warrants (the “Private Placement Warrants”), which included
697,500 Private Placement Warrants issued pursuant to the full exercise of the over-allotment option granted to the underwriters, to
NorthView Sponsor I, LLC (“the Sponsor”), I-Bankers Securities, Inc., and Dawson James Securities, Inc. at a purchase price
of $1.00 per Private Placement Warrant, generating gross proceeds to the Company of $7,347,500, which is discussed in Note 4.
Transaction costs amounted to $7,959,726 consisting
of $3,450,000 of underwriting discount, $3,570,576 of Representative’s Shares cost, $259,527 of Representative’s Warrants
cost and $679,623 of other offering costs.
The Company’s Business Combination must
be with one or more target businesses that together have a fair market value equal to at least 80% of the value of the assets held in
the Trust Account (as defined below) (excluding taxes payable on the interest earned on the Trust Account) at the time of the signing
a definitive agreement in connection with the initial Business Combination. However, the Company will only complete a Business Combination
if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires
a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company
Act. There is no assurance that the Company will be able to successfully effect a Business Combination.
Following the closing of the Public Offering
on December 22, 2021, an amount of $191,647,500 ($10.10 per Unit), excluding $741,228 that was wired to the Company’s operating
bank account on December 31, 2021 for working capital purposes, from the net proceeds of the sale of the public units in the IPO and
the sale of the Private Placement Warrants was placed in a Trust Account (“Trust Account”) and invested in United States
government treasury bills with a maturity of 185 days or less or in money market funds investing solely in United States Treasuries and
meeting certain conditions under Rule 2a-7 under the Investment Company Act as determined by the Company. Except with respect to interest
earned on the funds held in the Trust Account that may be released to the Company to pay its taxes, if any, the proceeds from the IPO
will not be released from the Trust Account until the earliest of (i) the completion of the Company’s initial Business Combination,
(ii) the redemption of any public shares properly tendered in connection with a stockholder vote to amend the Company’s amended
and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to redeem 100% of the
public shares if the Company does not complete the initial Business Combination within the extended period (or any additional extension
from the closing of our IPO if we extend the period of time to consummate a business combination) (the “Combination Period”),
or (B) with respect to any other provision relating to stockholders’ rights or pre-Business Combination activity, and (iii) the
redemption of all of the Company’s public shares if the Company is unable to complete the Business Combination within the Combination
Period, subject to applicable law. The proceeds deposited in the Trust Account could become subject to the claims of the Company’s
creditors, if any, which could have priority over the claims of the Company’s public stockholders.
The Company will provide its public stockholders
with the opportunity to redeem all or a portion of their public shares upon the completion of the initial Business Combination either
(i) in connection with a stockholder meeting called to approve the initial Business Combination or (ii) by means of a tender
offer. The decision as to whether the Company will seek stockholder approval of a proposed initial Business Combination or conduct a
tender offer will be made by the Company, solely in its discretion. The stockholders will be entitled to redeem all or a portion of their
public shares upon the completion of the initial Business Combination at a per-share price, payable in cash, equal to the aggregate
amount then on deposit in the Trust Account as of two business days prior to the consummation of the initial Business Combination, including
interest (which interest shall be net of taxes payable) divided by the number of then outstanding public shares, subject to the limitations
described herein. The per share amount the Company will distribute to investors who properly redeem their shares will not be reduced
by the fee payable to I-Bankers and Dawson James pursuant to the Business Combination Marketing Agreement (see Note 6).
If the Company is unable to complete an initial
Business Combination within the Combination Period, it will: (i) cease all operations except for the purpose of winding up, (ii) as promptly
as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash,
equal to the aggregate amount then on deposit in the Trust account, including interest (which interest shall be net of taxes payable,
and less up to $100,000 of interest to pay dissolution expenses) divided by the number of then outstanding public shares, which redemption
will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions,
if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of
the Company’s remaining stockholders and its board of directors, dissolve and liquidate, subject in each case to the Company’s
obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption
rights or liquidating distributions with respect to the Company’s rights and warrants, which will expire worthless if the Company
fails to complete the Business Combination within the Combination Period.
All of the Public Shares, or shares of our common
stock sold as part of the IPO, contain a redemption feature which allows for the redemption of such Public Shares in connection with
our liquidation, if there is a stockholder vote or tender offer in connection with our initial business combination and in connection
with certain amendments to our amended and restated certificate of incorporation. In accordance with SEC and its guidance on redeemable
equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of a company require
common stock subject to redemption to be classified outside of permanent equity. Given that the Public Shares were issued with other
freestanding instruments (i.e., public warrants), the initial carrying value of common stock classified as temporary equity was the allocated
proceeds determined in accordance with ASC 470-20. The common stock is subject to ASC 480-10-S99. If it is probable that the equity instrument
will become redeemable, we have the option to either (i) accrete changes in the redemption value over the period from the date of issuance
(or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the
instrument or (ii) recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument
to equal the redemption value at the end of each reporting period. We have elected to recognize the changes immediately. While redemptions
cannot cause the Company’s net tangible assets to fall below $5,000,001, the Public Shares are redeemable and will be classified
as such on the condensed consolidated balance sheets until such date that a redemption event takes place.
The Sponsor, officers and directors have agreed
to (i) waive their redemption rights with respect to their Founder Shares and public shares in connection with the completion of the
initial Business Combination, (ii) waive their rights to liquidating distributions from the Trust Account with respect to their Founder
Shares if the Company fails to complete the initial Business Combination within the Combination Period (although they will be entitled
to liquidating distributions from the Trust Account with respect to any public shares they hold if the Company fails to complete the
Business Combination within such time period); and (iii) vote their Founder Shares and any public shares purchased during or after the
IPO in favor of the initial Business Combination.
The Company’s Sponsor has agreed that it
will be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a
prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in
the Trust Account to below (i) $10.10 per public share or (ii) such lesser amount per public share held in the Trust Account as of the
date of the liquidation of the Trust Account due to reductions in value of the trust assets, in each case net of the amount of interest
which may be released to the Company to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights
to seek access to the Trust Account and except as to any claims under indemnity of the underwriters of the IPO against certain liabilities,
including liabilities under the Securities Act. Moreover, in the event that an executed waiver is deemed to be unenforceable against
a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims.
Liquidity and Going Concern
As of September 30, 2023, the Company had
$17,342 in cash and a working capital deficit of $2,846,203. Prior to the completion of the Company’s IPO, the Company’s
liquidity needs had been satisfied through a capital contribution from the Sponsor of $25,000 for the founder shares to cover certain
of the offering costs and the loan under an unsecured promissory note from the Sponsor of $204,841, which was fully paid upon the IPO.
Subsequent to the consummation of the Initial Public Offering and Private Placement, the Company’s liquidity needs have been satisfied
through the proceeds from the consummation of the Private Placement not held in the Trust Account, and the drawdowns on the convertible
promissory note.
In order to finance transaction costs in connection
with an intended Business Combination, the initial stockholders or an affiliate of the initial stockholders or certain of the Company’s
officers and directors may, but are not obligated to, provide the Company Working Capital Loans (see Note 5).
On April 27, 2023, the Company signed a Convertible
Working Capital Promissory Note (“the Note”) with the Sponsor for $1,200,000. The Note is non-interest bearing and is due
the earlier of the consummation of a business combination or the date of liquidation. The Sponsor may elect to convert all or any portion
of the unpaid principal balance of this Note into warrants, at a price of $1.00 per warrant. The Company had principal outstanding of
$713,015 and is presenting the Note at fair value on its balance sheet at September 30, 2023 in the amount of $601,239.
The Company has until as late as December 22,
2023 to consummate a Business Combination. It is uncertain that the Company will be able to consummate a Business Combination by as late
as December 22, 2023. If a Business Combination is not consummated by the required date, there will be an option to either extend the
time available for us to consummate our initial business combination or execute a mandatory liquidation and subsequent dissolution. In
connection with the Company’s assessment of going concern considerations in accordance with the authoritative guidance in Financial
Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, “Disclosure of Uncertainties
About an Entity’s Ability to Continue as a Going Concern,” management has determined that mandatory liquidation, and subsequent
dissolution, should the Company be unable to complete a business combination, raises substantial doubt about the Company’s ability
to continue as a going concern for the next twelve months from the issuance of these condensed consolidated financial statements. No
adjustments have been made to the carrying amounts of assets and liabilities should the Company be required to liquidate after December
22, 2023.
The Company held a meeting on March 10, 2023
to vote on the proposal to amend the Company’s amended and restated certificate of incorporation to extend the date by which the
Company must consummate a business combination or, if it fails to do so, cease its operations and redeem or repurchase 100% of the shares
of the Company’s common stock issued in the Company’s initial public offering, from March 22, 2023, monthly for up to
nine additional months at the election of the Company, ultimately until as late as December 22, 2023 (the “Extension”,
and such extension date the “Extended Date”). During the three and nine months ended September 30, 2023, the Company paid
$146,120 and $340,947, respectively, in extension payments. On March 22, 2023, 18,000,868 shares of the Company’s common stock
were redeemed with a total redemption payment of $184,845,836.
Risks and Uncertainties
Management is continuing to evaluate the impact
of the COVID-19 pandemic and the Russia-Ukraine war and has concluded that while it is reasonably possible that it could have a negative
effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is
not readily determinable as of the date of these unaudited condensed consolidated financial statements. The unaudited condensed consolidated
financial statements do not include any adjustments that might result from the outcome of this uncertainty.
On August 16, 2022, the Inflation Reduction Act
of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise
tax on certain repurchases of stock occurring on or after January 1, 2023, by publicly traded U.S. domestic corporations, by certain
U.S. domestic subsidiaries of publicly traded foreign corporations, by “covered surrogate foreign corporations” (as defined
in the IR Act) and by certain affiliates of the foregoing. The excise tax is imposed on the repurchasing corporation itself, not its
shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased
at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the
fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In
addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the “Treasury”) has been given
authority to provide regulations and other guidance to carry out, and to prevent the avoidance of the excise tax.
Any redemption or other repurchase that occurs
after December 31, 2022, in connection with a Business Combination, extension vote or otherwise, may be subject to the excise tax. Whether
and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise
would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the Business
Combination, extension or otherwise, (ii) the structure of a Business Combination, (iii) the nature and amount of any “PIPE”
or other equity issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination
but issued within the same taxable year of a Business Combination) and (iv) the content of regulations and other guidance from the Treasury.
In addition, because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment
of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business
Combination and in the Company’s ability to complete a Business Combination.
On March 22, 2023, the Company’s stockholders
redeemed 18,000,868 shares for a total of $184,845,836. The Company determined that an excise tax liability should be recorded due to
the redeemed shares. As of September 30, 2023, the Company has a charge to stockholders’ deficit of $1,848,455 of excise tax liability
calculated as 1% of the value of shares redeemed.
Note 2 – Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated
financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of
America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not
include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed consolidated financial
statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances
and results for the periods presented. The interim results for the three and nine months ended September 30, 2023 are not necessarily
indicative of the results to be expected for the year ending December 31, 2023 or for any future periods.
The accompanying unaudited condensed consolidated
financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in
the Form 10-K annual report filed by the Company with the SEC on March 6, 2023.
Principles of Consolidation
The accompanying condensed consolidated financial
statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions
have been eliminated in consolidation.
Emerging Growth Company Status
The Company is an “emerging growth company,”
as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”),
and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that
are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public
accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive
compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote
on executive compensation and stockholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make
comparison of the Company’s unaudited condensed consolidated financial statements with another public company, which is neither
an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible
because of the potential differences in accounting standards used.
Use of Estimates
The preparation of these unaudited condensed
consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated
financial statements.
Making estimates requires management to exercise
significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances
that existed at the date of the unaudited condensed consolidated financial statements, which management considered in formulating its
estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly
from those estimates.
Concentration of Credit Risk
Financial instruments that potentially subject
the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal
Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account.
Cash and Cash Equivalents
The Company considers all short-term investments
with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents
as of September 30, 2023 and December 31, 2022.
Cash and Marketable Securities Held in Trust
Account
At September 30, 2023 and December 31, 2022,
the assets held in the Trust Account were held in U.S. Treasury Bills with a maturity of 185 days or less and in
money market funds which invest in U.S. Treasury securities.
During the nine months ended September 30, 2023,
pursuant to the trust agreement dated as of December 20, 2021 between the Company and Continental Stock Transfer & Trust Company
(“CST”), the trustee of the Trust Account, $1,171,438 of interest income from the Trust Account was withdrawn by the Company
for the payment of its taxes.
At December 31, 2022 the Company classified its
US Treasury bills as held-to-maturity in accordance with FASB ASC Topic 320 “Investments - Debt and Equity Securities.” Held-to-maturity
securities are those securities which the Company has the ability and intent to hold until maturity. Held-to-maturity treasury securities
are recorded at amortized cost and adjusted for the amortization or accretion of premiums or discounts.
A decline in the market value of held-to-maturity
securities below cost that is deemed to be other than temporary, results in an impairment that reduces the carrying costs to such securities’
fair value. The impairment is charged to earnings and a new cost basis for the security is established. To determine whether an impairment
is other than temporary, the Company considers whether it has the ability and intent to hold the investment until a market price recovery
and considers whether evidence indicating the cost of the investment is recoverable outweighs evidence to the contrary. Evidence considered
in this assessment includes the reasons for the impairment, the severity and the duration of the impairment, changes in value subsequent
to year-end, forecasted performance of the investee, and the general market condition in the geographic area or industry in which the
investee operates.
Premiums and discounts are amortized or accreted
over the life of the related held-to-maturity security as an adjustment to yield using the effective-interest method. Such amortization
and accretion are included in the “interest income” line item in the unaudited condensed consolidated statements of operations.
Interest income is recognized when earned.
The carrying value, excluding gross unrealized
holding (gain) loss, and fair value of held to maturity securities as of December 31, 2022 are as follows:
| |
Carrying Value as of December 31, 2022 | | |
Gross Unrealized Gains | | |
Gross Unrealized Losses | | |
Fair Value as of December 31, 2022 | |
Cash | |
$ | 1,034 | | |
$ | — | | |
$ | — | | |
$ | 1,034 | |
U.S. Treasury Bills | |
| 194,223,748 | | |
| 43,626 | | |
| — | | |
| 194,267,374 | |
| |
$ | 194,224,782 | | |
$ | 43,626 | | |
$ | — | | |
$ | 194,268,408 | |
Effective January 1, 2023, the Company changed
its accounting policy for the investments in trust to the fair value method.
As of September 30, 2023, substantially all of
the assets held in the Trust Account were held in mutual funds that invest in U.S Treasury Securities. The Company’s investments
held in the Trust Account are now classified as trading securities. Trading securities are presented on the balance sheet at fair value
at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are
included in in the statements of operations for the three and nine months ended September 30, 2023. The estimated fair values of investments
held in Trust Account are determined using available market information.
Fair Value of Financial Instruments
The fair value of the Company’s assets
and liabilities approximates the carrying amounts represented in the accompanying condensed consolidated balance sheets, primarily due
to their short-term nature, except for the warrant liabilities, convertible promissory note and investments in the Trust Account.
Income Taxes
The Company accounts for income taxes under ASC
740, “Income Taxes.” ASC 740, Income Taxes, requires the recognition of deferred tax assets and liabilities for both the expected
impact of differences between the unaudited condensed consolidated financial statements and tax basis of assets and liabilities and for
the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance
to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. As of September 30,
2023 and December 31, 2022, the Company’s deferred tax asset had a full valuation allowance recorded against it. Our effective tax
rate was (7.46%) and 2.38% for the three months ended September 30, 2023 and 2022, respectively, and 31.74% and 1.03% for the nine months
ended September 30, 2023 and 2022, respectively. The effective tax rate differs from the statutory tax rate of 21% for the three and nine
months ended September 30, 2023 and 2022, due to changes in fair value of warrant liabilities, and the valuation allowance on the deferred
tax assets.
ASC 740 also clarifies the accounting for uncertainty
in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process
for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits
to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides
guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.
The Company recognizes interest and penalties
related to unrecognized tax benefits as a formation cost expense. The Company is currently not aware of any issues under review that could
result in significant payments, accruals or material deviation from its position. Interest and penalties expense amounted to $0 and $19,158
during the three and nine months ended September 30, 2023, respectively, and $0 during the three and nine months ended September 30, 2022.
The Company has identified the United States
as its only “major” tax jurisdiction. The Company is subject to income taxation by major taxing authorities since inception.
These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and
compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax
benefits will materially change over the next twelve months.
Derivative Financial Instruments
The Company evaluates its financial instruments,
such as warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance
with ASC Topic 815, “Derivatives and Hedging”. Derivative instruments are initially recorded at fair value on the grant date
and re-valued at each reporting date, with changes in the fair value reported in the unaudited condensed consolidated statements
of operations. Derivative assets and liabilities are classified in the condensed consolidated balance sheets as current or non-current based
on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet
date.
Convertible Promissory Note
The fair value of the Company’s convertible
promissory note is valued using a compound option formula on the convertible feature and a present value of the host contract. The valuation
technique requires inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s
own assumption about the assumptions a market participant would use in pricing the working capital loan.
Warrant Liabilities
The Company accounts for the 17,404,250 warrants
issued in connection with the IPO (the 9,487,500 Public Warrants, the 7,347,500 Private Placement Warrants, and the 569,250 Representative
Warrants inclusive of the underwriters’ over-allotment option) in accordance with the guidance contained in ASC 815-40. Such
guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as
a liability. Accordingly, the Company has classified each warrant as a liability at its fair value. This liability is subject to re-measurement at
each balance sheet date. With each such re-measurement, the warrant liabilities will be adjusted to fair value, with the change in fair
value recognized in the Company’s unaudited condensed consolidated statements of operations (See Note 8).
Offering Costs associated with the Initial
Public Offering
The Company complies with the requirements of
ASC 340-10-S99-1, SEC Staff Accounting bulletin Topic 5A – “Expenses of Offering”, and SEC Staff Accounting bulletin
Topic 5T – “Accounting for Expenses or Liabilities Paid by Principal Stockholder(s)”. Offering costs consist principally
of professional and registration fees incurred through the balance sheet date that are related to the IPO. Offering costs directly attributable
to the issuance of an equity contract to be classified in equity are recorded as a reduction of equity. Offering costs for equity contracts
that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $7,959,726 as
a result of the IPO (consisting of $3,450,000 of underwriting fees, $3,570,576 of Representative’s Shares cost,
$259,527 of Representative’s Warrants cost and $679,623 of other offering costs). The Company recorded $7,701,178 of
offering costs as a reduction of temporary equity in connection with the common stock included in the Units. The Company immediately
expensed $258,548 of offering costs in connection with the Public Warrants, Private Placement Warrants and Representative’s
Warrants that were classified as liabilities.
Net (Loss) Income Per Common Stock
The Company has two categories of shares,
which are referred to as common stock subject to possible redemption and common stock. Earnings and losses are shared pro rata
between the two categories of shares. The 17,404,250 potential shares of common stock for outstanding warrants to purchase
the Company’s shares were excluded from diluted earnings per share for the three and nine months ended September 30, 2023 and
2022 because the warrants are contingently exercisable, and the contingencies have not yet been met. As a result, diluted net (loss)
income per share of common stock is the same as basic net (loss) income per share of common stock for the periods
presented. The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net
(loss) income per share for each category of common stock:
| |
For the Three Months Ended September 30, | | |
For the Nine Months Ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
Common stock subject to possible redemption | | |
Common stock | | |
Common stock subject to possible redemption | | |
Common stock | | |
Common stock subject to possible redemption | | |
Common stock | | |
Common stock subject to possible redemption | | |
Common stock | |
Basic and diluted net (loss) income per share: | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
Numerator: | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
Allocation of net (loss) income | |
$ | (58,017 | ) | |
$ | (309,328 | ) | |
$ | 1,384,778 | | |
$ | 379,035 | | |
$ | 503,233 | | |
$ | 422,706 | | |
$ | 5,248,577 | | |
$ | 1,436,616 | |
Denominator: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Weighted-average shares outstanding | |
| 974,132 | | |
| 5,193,750 | | |
| 18,975,000 | | |
| 5,193,750 | | |
| 6,183,174 | | |
| 5,193,750 | | |
| 18,975,000 | | |
| 5,193,750 | |
Basic and diluted net (loss) income per share | |
$ | (0.06 | ) | |
$ | (0.06 | ) | |
$ | 0.07 | | |
$ | 0.07 | | |
$ | 0.08 | | |
$ | 0.08 | | |
$ | 0.28 | | |
$ | 0.28 | |
Common Stock Subject to Possible Redemption
The Company’s common stock sold as part
of the Units in the IPO (“public common stock”) contain a redemption feature which allows for the redemption of such public
shares in connection with the Company’s liquidation, or if there is a stockholder vote or tender offer in connection with the Company’s
initial Business Combination. In accordance with ASC 480-10-S99, the Company classifies public common stock outside of permanent equity
as the redemption provisions are not solely within the control of the Company. The public common stock was issued with other freestanding
instruments (i.e., Public Warrants) and as such, the initial carrying value of public common stock classified as temporary equity was
the allocated proceeds determined in accordance with ASC 470-20.
As of September 30, 2023 and December 31, 2022,
the amount of public common stock reflected on the condensed consolidated balance sheets is reconciled in the following table:
Gross proceeds | |
$ | 189,750,000 | |
Less: | |
| | |
Proceeds allocated to Public Warrants | |
| (4,204,248 | ) |
Common stock issuance costs | |
| (7,701,178 | ) |
Plus: | |
| | |
Accretion of redeemable common stock | |
| 15,680,910 | |
Contingently redeemable common stock, December 31, 2022 | |
| 193,525,484 | |
Less: | |
| | |
Partial redemption | |
| (184,845,836 | ) |
Plus: | |
| | |
Accretion of redeemable common stock | |
| 1,941,333 | |
Contingently redeemable common stock, September 30, 2023 | |
$ | 10,620,981 | |
Recently Issued Accounting Standards
In June 2016, the FASB issued Accounting Standards
Update (“ASU”) 2016-13 – Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on
Financial Instruments (“ASU 2016-13”). This update requires financial assets measured at amortized cost basis to be presented
at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events,
including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported
amount. Since June 2016, the FASB issued clarifying updates to the new standard including changing the effective date for smaller reporting
companies. The guidance is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal
years, with early adoption permitted. The Company adopted ASU 2016-13 on January 1, 2023. The adoption of ASU 2016-13 did not have a
material impact on its financial statements.
Management does not believe that any other recently
issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited
condensed consolidated financial statements.
Note 3 – Initial Public Offering
Public Units
On December 22, 2021, the Company sold 18,975,000
Units, (which included 2,475,000 Units issued pursuant to the full exercise of the over-allotment option) at a purchase price of $10.00
per Unit. Each unit that the Company is offering has a price of $10.00 and consists of one share of common stock, one right, and one-half of
one redeemable warrant. Each right entitles the holder thereof to receive one-tenth (1/10) of one share of common stock upon the
consummation of an initial business combination. Each whole warrant entitles the holder thereof to purchase one share of common stock
at a price of $11.50 per share, subject to adjustment as described herein.
Public Warrants
Each whole warrant entitles the holder to purchase
one share of common stock at a price of $11.50 per share, subject to adjustment as discussed herein. In addition, if (x) the
Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the
closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per share of common stock
(with such issue price or effective issue price to be determined in good faith by the board of directors and, in the case of any such
issuance to the initial stockholders or their affiliates, without taking into account any founder shares held by such stockholders or
their affiliates, as applicable, prior to such issuance (the “Newly Issued Price”)), (y) the aggregate gross proceeds
from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for funding the initial
Business Combination (net of redemptions), and (z) the volume weighted average trading price of the common stock during the 20 trading
day period starting on the trading day prior to the day on which the Company consummates the Business Combination (such price, the “Market
Value”) is below $9.20 per share, the exercise price shall be adjusted (to the nearest cent) to be equal to 115% of the
higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described in the section
“Redemption of warrants” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value
and the Newly Issued Price.
The warrants will become exercisable on the later
of 12 months from the closing of the IPO or 30 days after the completion of its initial Business Combination and will expire
five years after the completion of the Company’s initial Business Combination, at 5:00 p.m., New York City time, or earlier
upon redemption or liquidation.
The Company has agreed that as soon as practicable,
but in no event later than 15 business days after the closing of the initial Business Combination, the Company will use its reasonable
best efforts to file, and within 60 business days after the closing of the initial Business Combination, to have declared effective,
a registration statement relating to those shares of common stock, and to maintain a current prospectus relating to such shares of common
stock until the warrants expire or are redeemed. Notwithstanding the foregoing, if a registration statement covering the shares of common
stock issuable upon exercise of the warrants is not effective within the above specified period following the consummation of the initial
Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when
the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to the
exemption provided by Section 3(a)(9) of the Securities Act of 1933, as amended, or the Securities Act, provided that such exemption
is available. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless
basis.
Redemption of Warrants
Once the warrants become exercisable, the Company
may redeem the outstanding warrants:
| ● | in
whole and not in part; |
| ● | at
a price of $0.01 per warrant; |
| ● | upon
a minimum of 30 days’ prior written notice of redemption (the “30-day redemption period”); |
| ● | if,
and only if, the last sale price of the common stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day
period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. |
If the Company calls the warrants for redemption
as described above, management will have the option to require all holders that wish to exercise warrants to do so on a “cashless
basis.” In determining whether to require all holders to exercise their warrants on a “cashless basis,” management
will consider, among other factors, the Company’s cash position, the number of warrants that are outstanding and the dilutive effect
on the stockholders of issuing the maximum number of shares of common stock issuable upon the exercise of the warrants. In such event,
each holder would pay the exercise price by surrendering the warrants for that number of shares of common stock equal to the quotient
obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the difference
between the exercise price of the warrants and the “fair market value” (defined below) by (y) the fair market value.
The “fair market value” shall mean the average reported last sale price of the common stock for the 10 trading days ending
on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants.
Note 4 – Private Placement
The Company’s Sponsor, I-Bankers and Dawson
James have purchased an aggregate of 7,347,500 Private Placement Warrants (which included 697,500 Private Placement Warrants issued pursuant
to the full exercise of the over-allotment option) at a price of $1.00 per warrant ($7,347,500 in the aggregate) in a private placement
that closed simultaneously with the closing of the IPO. Of such amount, 5,162,500 Private Placement Warrants were purchased by the Sponsor
and 2,185,000 Private Placement Warrants were purchased by I-Bankers and Dawson James.
The Private Placement Warrants are identical
to the warrants included in the units sold in the IPO, except that the Private Placement Warrants: (i) will not be redeemable by the
Company and (ii) may be exercised for cash or on a cashless basis, in each case so long as they are held by the initial purchasers or
any of their permitted transferees. If the Private Placement Warrants are held by holders other than the initial purchasers or any of
their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by the holders on the same
basis as the warrants included in the Units being sold in the IPO.
Note 5 – Related Party Transactions
Founder Shares
In April 2021, the Sponsor paid $25,000, or approximately
$0.005 per share, to cover certain of the offering costs in exchange for an aggregate of 5,175,000 shares of common stock, par value
$0.0001 per share (the “Founder Shares”). In October 2021, the Sponsor irrevocably surrendered to the Company for cancellation
and for no consideration 862,500 shares of common stock. On December 20, 2021, the Company effected a 1.1- for-1 stock dividend of its
common stock, resulting in the Sponsor holding an aggregate of 4,743,750 shares of common stock. The Founder Shares include an aggregate
of up to 618,750 shares subject to forfeiture if the over-allotment option is not exercised by the underwriters in full. On December
22, 2021, the over-allotment option was fully exercised and such shares are no longer subject to forfeiture.
The Sponsor has agreed not to transfer, assign
or sell any of their Founder Shares until the earlier to occur of: (A) one year after the completion of the initial Business Combination
or (B) the date on which the Company completes a liquidation, merger, stock exchange or other similar transaction after the initial Business
Combination that results in all of the Company’s public stockholders having the right to exchange their shares of common stock
for cash, securities or other property (the “Lock-up”). Notwithstanding the foregoing, if the last sale price of the Company’s
common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and
the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination,
the Founder Shares will be released from the Lock-up.
Convertible Promissory Note – Related
Party
On April 27, 2023, the Company signed a Convertible
Working Capital Promissory Note (“the Note”) with the Sponsor for $1,200,000. The Note is non-interest bearing and is due
the earlier of the consummation of a business combination or the date of liquidation. The Sponsor may elect to convert all or any portion
of the unpaid principal balance of this Note into warrants, at a price of $1.00 per warrant. As of September 30, 2023, the Company had
principal outstanding of $713,015 and is presenting the Note at fair value on its balance sheet at September 30, 2023 in the amount of
$601,239.
Promissory Note – Related Party
On April 19, 2021, the Company issued an unsecured
promissory note to the Sponsor, pursuant to which the Company may borrow up to an aggregate principal amount of $150,000 to be used for
a portion of the expenses of the IPO. This loan is non-interest bearing, unsecured and was to be due at the earlier of September 30,
2021 or the closing of the IPO. On November 5, 2021, the Company amended the promissory note to increase the principal amount up to $200,000
with a due date at the earlier of April 30, 2022 or the closing of the IPO.
Through the IPO, the Company borrowed $200,000
under the promissory note and an additional $4,841 was advanced from the Sponsor. These amounts were repaid in full upon the closing
of the IPO out of the offering proceeds that had been allocated to the payment of offering expenses (other than underwriting commissions).
The Company paid $25,000 in excess which was owed back to the Company upon the closing of the IPO and was returned by the Sponsor on
June 15, 2022.
Related Party Loans
In order to finance transaction costs in connection
with an intended initial Business Combination, the initial stockholders or an affiliate of the initial stockholders or certain of the
Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (the “Working Capital
Loans”). If the Company completes the initial Business Combination, the Company would repay such loaned amounts out of the proceeds
of the Trust Account released to the Company. Otherwise, such loans would be repaid only out of funds held outside the Trust Account.
In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside
the Trust Account to repay such loaned amounts but no proceeds from the Trust Account would be used to repay such loaned amounts. Up
to $1,500,000 of such loans may be convertible, at the option of the lender, into warrants at a price of $1.00 per warrant of the post
Business Combination entity. The warrants would be identical to the Private Placement Warrants, including as to exercise price, exercisability
and exercise period. At September 30, 2023 and December 31, 2022, the Company had no borrowings under the Working Capital Loans, other
than the Note described in “Note 5 – Related Party Transactions – Convertible Promissory Note – Related Party”.
Administrative Service Fee
Commencing on the effective date of the IPO, the
Company began paying its Sponsor a total of $5,000 per month for office space, utilities, secretarial support and other administrative
and consulting services. As of June 30, 2023, the Company and the Sponsor terminated this agreement. For the three and nine months ended
September 30, 2023, $0 and $30,000, respectively, had been incurred and billed relating to the administrative service fee. For the
three and nine months ended September 30, 2022, $15,000 and $48,387, respectively, had been incurred relating to the administrative service
fee. As of September 30, 2023 and December 31, 2022, $55,000 and $25,000, respectively, relating to the administrative service fee was
not paid and recorded as due to related party.
Note 6 – Commitments and Contingencies
Registration Rights
The holders of the Founder Shares, the Private
Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any underlying securities) are entitled
to registration rights pursuant to a registration rights agreement signed on the closing date of the IPO requiring the Company to register
such securities for resale. The holders of these securities are entitled to make up to three demands, excluding short form demands, that
the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect
to registration statements filed subsequent to the completion of the initial Business Combination. However, the registration rights agreement
provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination
of the applicable Lock-up period described in Note 5. The Company will bear the expenses incurred in connection with the filing
of any such registration statements.
Underwriters Agreement
The underwriters had a 30-day option from
the date of IPO to purchase up to an additional 2,475,000 units to cover over-allotments, if any. On December 22, 2021, the
over-allotment was fully exercised.
The underwriters received a cash underwriting
discount of approximately 1.82% of the gross proceeds of the IPO, or $3,450,000.
Business Combination Marketing Agreement
Under a Business Combination marketing agreement,
the Company engaged I-Bankers and Dawson James as advisors in connection with the Business Combination to assist the Company in holding
meetings with the stockholders to discuss the potential Business Combination and the target business’s attributes, introduce the
Company to potential investors that are interested in purchasing the Company’s securities in connection with the potential Business
Combination, assist the Company in obtaining stockholder approval for the Business Combination and assist the Company with its press
releases and public filings in connection with the Business Combination. The Company was obligated to pay I-Bankers and Dawson James
a cash fee for such marketing services upon the consummation of the initial Business Combination in an amount of 3.68% of the gross
proceeds of the IPO, or $6,986,250. The agreement was amended on November 7, 2022 and calls for the 3.68% business combination fee to
be paid as (a) 27.5% cash and (b) 72.5% to be rolled into equity at closing.
Representative’s Shares
On December 22, 2021, the Company issued 450,000 shares
(Representative Shares) of common stock (which included 37,500 Representative Shares issued pursuant to the full exercise of
the over-allotment option) at the consummation of the IPO to I-Bankers and Dawson James (and/or their designees). I-Bankers and
Dawson James (and/or their designees) have agreed not to transfer, assign or sell any such shares until the completion of the initial
Business Combination. In addition, I-Bankers and Dawson James (and/or their designees) have agreed (i) to waive their redemption
rights with respect to such shares in connection with the completion of the initial Business Combination and (ii) to waive their
rights to liquidating distributions from the Trust Account with respect to such shares if the Company fails to complete its initial Business
Combination within the Combination Period. The fair value of the Representative’s Shares issued are recognized as offering
costs directly attributable to the issuance of an equity contract to be classified in equity and are recorded as a reduction of equity
(see Note 1). The fair value of the Representative’s Shares of $3,570,576 was determined utilizing a Monte Carlo simulation
with the following inputs at December 22, 2021:
| |
December 22, 2021 | |
Input | |
| |
Risk-free interest rate | |
| 0.76 | % |
Expected term (years) | |
| 2.27 | |
Expected volatility | |
| 11.4 | % |
Stock price | |
$ | 10.00 | |
Fair value of Representative’s Shares | |
$ | 7.93 | |
Representative’s Warrants
The Company granted to I-Bankers and Dawson
James (and/or their designees) 569,250 warrants (which included 74,250 warrants issued pursuant to the full exercise
of the over-allotment option) exercisable at $11.50 per share (or an aggregate exercise price of $6,546,375) at the closing of the
IPO. The Representative Warrants issued are recognized as derivative liabilities in accordance with ASC 815-40 and recorded as liabilities
at fair value each reporting period (see Notes 1 and 8). The warrants may be exercised for cash or on a cashless basis, at the holder’s
option, at any time during the period commencing on the later of the first anniversary of the effective date of the registration statement
of which the IPO forms a part and the closing of the initial Business Combination and terminating on the fifth anniversary of such effectiveness
date. Notwithstanding anything to the contrary, I-Bankers and Dawson James have agreed that neither they nor their designees will
be permitted to exercise the warrants after the five year anniversary of the effective date of the registration statement of
which the IPO forms a part. The warrants and such shares purchased pursuant to the warrants have been deemed compensation by FINRA and
are therefore subject to a lock-up for a period of 180 days immediately following the date of the effectiveness of the registration
statement of which the IPO forms a part pursuant to FINRA Rule 5110I(1). Pursuant to FINRA Rule 5110I(1), these securities
will not be the subject of any hedging, short sale, derivative, put or call transaction that would result in the economic disposition
of the securities by any person for a period of 180 days immediately following the effective date of the registration statement
of which the IPO forms a part, nor may they be sold, transferred, assigned, pledged or hypothecated for a period of 180 days immediately
following the effective date of the registration statement of which the IPO forms a part except to any underwriter and selected dealer
participating in the offering and their bona fide officers or partners. The warrants grant to holders demand and “piggy back”
rights for periods of five and seven years, respectively, from the effective date of the registration statement of which the IPO forms
a part with respect to the registration under the Securities Act of the shares issuable upon exercise of the warrants. The Company will
bear all fees and expenses attendant to registering the securities, other than underwriting commissions, which will be paid for by the
holders themselves. The exercise price and number of shares issuable upon exercise of the warrants may be adjusted in certain circumstances
including in the event of a share dividend, or the Company’s recapitalization, reorganization, merger or consolidation. However,
the warrants will not be adjusted for issuances of shares at a price below its exercise price. The Company will have no obligation to
net cash settle the exercise of the warrants. The holder of the warrants will not be entitled to exercise the warrants for cash unless
a registration statement covering the securities underlying the warrants is effective or an exemption from registration is available.
Merger Agreement
On November 7, 2022, NorthView entered into a
Merger Agreement and Plan of Reorganization (the “Merger Agreement”), by and among Merger Sub., and Profusa, Inc., a California
corporation (“Profusa”). The Merger Agreement provides that, among other things, at the closing of the transactions contemplated
by the Merger Agreement, Merger Sub will merge with and into Profusa (the “Merger”), with Profusa surviving as a wholly-owned
subsidiary of NorthView. In connection with the Merger, NorthView will change its name to “Profusa, Inc.”
The Business Combination is subject to customary
closing conditions, including the satisfaction of the minimum available cash condition of $15,000,000, the receipt of certain governmental
approvals and the required approval by the stockholders of NorthView and Profusa. There is no assurance that the Business Combination
will be completed.
The aggregate consideration to be received by
the Profusa stockholders is based on a pre-transaction equity value of $155,000,000. The exchange ratio will be equal to (a) $155,000,000,
divided by an assumed value of NorthView Common Stock of $10.00 per share. Subject to certain future revenue and stock-price based milestones,
Profusa stockholders will have the right to receive an aggregate of up to an additional 3,875,000 shares of NorthView Common Stock.
On September 12, 2023, the parties to the Merger
Agreement entered into Amendment No. 1 to the Merger Agreement (the “Amendment”) pursuant to which the parties agreed to
revise the revenue earnout milestones to reflect updated projections provided by Profusa. Specifically, Amendment No. 1 revised the definition
of “Milestone Event III” and “Milestone Event IV” such that one-quarter of the Earnout Shares would be issued
to Profusa stockholders if the combined company achieves Earnout Revenue of $11,864,000 for the fiscal year ended December 31, 2024,
and one-quarter of the Earnout Shares would be issued to Profusa stockholders if the combined company achieves Earnout Revenue of $99,702,000
for the fiscal year ended December 31, 2025. Amendment No. 1 also clarified the exercise price of certain of the Company’s Warrants.
Note 7 – Stockholders’ Deficit
Preferred stock — The
Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 and with such designations,
rights and preferences as may be determined from time to time by the Company’s board of directors. As of September 30, 2023
and December 31, 2022, there was no preferred stock issued or outstanding.
Common Stock — The Company
is authorized to issue a total of 100,000,000 shares of common stock at par value of $0.0001 each. In April 2021, the
Company issued 5,175,000 shares of common stock to its Sponsor for $25,000, or approximately $0.005 per share. In October
2021, the Sponsor irrevocably surrendered to the Company for cancellation and for no consideration 862,500 shares of common
stock. On December 20, 2021, the Company effected a 1.1- for-1 stock dividend of its common stock, resulting in an
aggregate of 4,743,750 Founder Shares issued and outstanding. On December 22, 2021, the Company has also issued 450,000 shares
(Representative’s Shares) of common stock (which included 37,500 Representative Shares issued pursuant to the full exercise
of the over-allotment option) at the consummation of the IPO to I-Bankers and Dawson James (and/or their designees). As of
September 30, 2023 and December 31, 2022, there were 5,193,750 shares of common stock issued and outstanding, excluding 974,132
and 18,975,000 shares of common stock subject to redemption, respectively.
Common stockholders of record are entitled to
one vote for each share held on all matters to be voted on by stockholders. Unless specified in the Company’s amended and restated
certificate of incorporation or bylaws, or as required by applicable provisions of the DGCL or applicable stock exchange rules, the affirmative
vote of a majority of the Company’s common stock that are voted is required to approve any such matter voted on by the stockholders.
There is no cumulative voting with respect to the election of directors, with the result that the holders of more than 50% of the
shares voted for the election of directors can elect all of the directors (prior to consummation of the initial Business Combination).
The Company’s stockholders are entitled to receive ratable dividends when, as and if declared by the board of directors out of
funds legally available therefor.
Note 8 – Fair Value Measurements
Fair value is defined as the price that would
be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement
date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives
the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the
lowest priority to unobservable inputs (Level 3 measurements). The Company’s financial instruments are classified as either Level
1, Level 2 or Level 3. These tiers include:
| ● | Level
1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; |
| ● | Level
2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices
for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and |
| ● | Level
3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions,
such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. |
The following tables present information about
the Company’s assets and liabilities that are measured at fair value on September 30, 2023 and December 31, 2022, and indicates
the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:
| |
September 30, 2023 | | |
Quoted Prices In Active Markets (Level 1) | | |
Significant Other Observable Inputs (Level 2) | | |
Significant Other Unobservable Inputs (Level 3) | |
Assets: | |
| | |
| | |
| | |
| |
Cash and marketable securities held in trust | |
$ | 10,651,566 | | |
$ | 10,651,566 | | |
| — | | |
| — | |
Liabilities: | |
| | | |
| | | |
| | | |
| | |
Warrant liabilities – Public Warrants | |
$ | 351,038 | | |
$ | 351,038 | | |
$ | — | | |
$ | — | |
Warrant liabilities – Private Placement Warrants | |
| 293,900 | | |
| — | | |
| — | | |
| 293,900 | |
Warrant liabilities – Representative’s Warrants | |
| 22,770 | | |
| — | | |
| — | | |
| 22,770 | |
Convertible promissory note | |
| 601,239 | | |
| — | | |
| — | | |
| 601,239 | |
Total | |
$ | 1,268,947 | | |
$ | 351,038 | | |
$ | — | | |
$ | 917,909 | |
| |
December 31, 2022 | | |
Quoted Prices In Active Markets (Level 1) | | |
Significant Other Observable Inputs (Level 2) | | |
Significant Other Unobservable Inputs (Level 3) | |
Liabilities: | |
| | |
| | |
| | |
| |
Warrant liabilities – Public Warrants | |
$ | 450,656 | | |
$ | 450,656 | | |
$ | — | | |
$ | — | |
Warrant liabilities – Private Placement Warrants | |
| 377,857 | | |
| — | | |
| — | | |
| 377,857 | |
Warrant liabilities – Representative’s Warrants | |
| 29,274 | | |
| — | | |
| — | | |
| 29,274 | |
Total | |
$ | 857,787 | | |
$ | 450,656 | | |
$ | — | | |
$ | 407,131 | |
The Company did not have any assets in the Trust
Account measured at fair value as of December 31, 2022.
The Public Warrants, the Private Placement Warrants
and the Representative’s Warrants were accounted for as liabilities in accordance with ASC 815-40 and are presented within liabilities
on the condensed consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis,
with changes in fair value presented within change in fair value of warrant liabilities in the unaudited condensed consolidated statements
of operations.
The Company utilized a Monte Carlo simulation
model for the initial valuation of the Public Warrants. The subsequent measurement of the Public Warrants at September 30, 2023 and December
31, 2022 was classified as Level 1 due to the use of an observable market quote in an active market. As of September 30, 2023 and December
31, 2022, the aggregate value of Public Warrants was $351,038 and $450,656, respectively.
The Company uses a Monte Carlo simulation model
to value the Private Placement Warrants and the Representative’s Warrants. The Company allocated the proceeds received from (i)
the sale of Units (which is inclusive of one shares of Common Stock and one-half of one Public Warrant) and (ii) the sale of Private
Placement Warrants, first to the warrants based on their fair values as determined at initial measurement, with the remaining proceeds
allocated to Common Stock subject to possible redemption (temporary equity) based on their relative fair values at the initial measurement
date. The Private Placement Warrants and the Representative’s Warrants were classified within Level 3 of the fair value hierarchy
at the measurement dates due to the use of unobservable inputs. Inherent in pricing models are assumptions related to expected share-price
volatility, expected life and risk-free interest rate. The Company estimates the volatility of its common stock based on historical volatility
that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield
curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed
to be equivalent to their remaining contractual term.
The key inputs into the Monte Carlo simulation
model for the warrant liabilities and convertible promissory note were as follows at September 30, 2023 and December 31, 2022:
| |
September 30, 2023 | | |
December 31, 2022 | |
Input | |
| | |
| |
Risk-free interest rate | |
| 5.50 | % | |
| 4.74 | % |
Expected term (years) | |
| 0.75 | | |
| 0.90 | |
Expected volatility | |
| 3.3 | % | |
| 7.7 | % |
Exercise price | |
$ | 11.50 | | |
$ | 11.50 | |
Fair value of Common stock | |
$ | 10.79 | | |
$ | 10.13 | |
The following table provides a summary of the
changes in the fair value of the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis for
the three and nine months ended September 30, 2023 and 2022:
| |
Private Placement Warrants | | |
Public Warrants | | |
Representative’s Warrants | | |
Warrant Liability | |
Fair value at December 31, 2022 | |
$ | 377,857 | | |
$ | — | | |
$ | 29,274 | | |
$ | 407,131 | |
Change in fair value of warrant liabilities | |
| 246,681 | | |
| — | | |
| 19,112 | | |
| 265,793 | |
Fair value at March 31, 2023 | |
| 624,538 | | |
| — | | |
| 48,386 | | |
| 672,924 | |
Change in fair value of warrant liabilities | |
| (433,503 | ) | |
| — | | |
| (33,585 | ) | |
| (467,088 | ) |
Fair value at June 30, 2023 | |
| 191,035 | | |
| — | | |
| 14,801 | | |
| 205,836 | |
Change in fair value of warrant liabilities | |
| 102,865 | | |
| — | | |
| 7,969 | | |
| 110,834 | |
Fair value at September 30, 2023 | |
$ | 293,900 | | |
$ | — | | |
$ | 22,770 | | |
$ | 316,670 | |
| |
Convertible Promissory Note | |
Fair value at December 31, 2022 | |
$ | — | |
Principal borrowing | |
| 713,015 | |
Change in fair value of convertible promissory note | |
| (111,776 | ) |
Fair value at September 30, 2023 | |
$ | 601,239 | |
| |
Private Placement Warrants | | |
Public Warrants | | |
Representative’s Warrants | | |
Warrant Liability | |
Fair value at December 31, 2021 | |
$ | 3,086,701 | | |
$ | 3,890,177 | | |
$ | 239,144 | | |
$ | 7,216,022 | |
Change in fair value of warrant liabilities | |
| (1,660,759 | ) | |
| (2,088,501 | ) | |
| (128,669 | ) | |
| (3,877,929 | ) |
Transfer out of Level 3 to Level 1 | |
| — | | |
| (1,801,676 | ) | |
| — | | |
| (1,801,676 | ) |
Fair value at March 31, 2022 | |
| 1,425,942 | | |
| — | | |
| 110,475 | | |
| 1,536,417 | |
Change in fair value of warrant liabilities | |
| (541,990 | ) | |
| — | | |
| (41,991 | ) | |
| (583,981 | ) |
Fair value at June 30, 2022 | |
| 883,952 | | |
| — | | |
| 68,484 | | |
| 952,436 | |
Change in fair value of warrant liabilities | |
| (468,803 | ) | |
| — | | |
| (36,321 | ) | |
| (505,124 | ) |
Fair value at September 30, 2022 | |
$ | 415,149 | | |
$ | — | | |
$ | 32,163 | | |
$ | 447,312 | |
Transfers to/from Levels 1, 2 and 3 are recognized
at the end of the reporting period. There was a transfer out of Level 3 to Level 1 for the fair value of the Public Warrants
when they began to trade separately from the Units during the three months ended March 31, 2022.
The fair value of the Company’s working
capital loan is valued using a compound option formula on the convertible feature and a present value of the host contract. The valuation
technique requires inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s
own assumption about the assumptions a market participant would use in pricing the working capital loan.
Note 9 – Subsequent Events
The Company evaluated subsequent events and transactions
that occurred after the balance sheet date up to the date that the unaudited condensed consolidated financial statements were issued.
Based on the Company’s review, the Company did not identify any subsequent events that would have required adjustment or disclosure
in the unaudited condensed consolidated financial statements.
Item 2. Management’s Discussion and
Analysis of Financial Condition and Results of Operations.
References to the “Company,” “NorthView
Acquisition Corp.,” “NorthView,” “our,” “us” or “we” refer to NorthView Acquisition
Corp. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction
with the unaudited condensed consolidated financial statements and the notes thereto contained elsewhere in this report. Certain information
contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q includes forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations and
projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions
about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future
results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you
can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,”
“expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,”
or the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but
are not limited to, those described in our other Securities and Exchange Commission (“SEC”) filings.
Overview
We are a blank check company incorporated on
April 19, 2021 as a Delaware corporation and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition,
stock purchase, reorganization or similar business combination with one or more businesses (a “Business Combination”). We
consummated our initial public offering on December 22, 2021 and are currently in the process of locating suitable targets for our business
combination. We intend to use the cash proceeds from our Public Offering and the Private Placement described below as well as additional
issuances, if any, of our capital stock, debt or a combination of cash, stock and debt to complete the Business Combination.
We expect to incur significant costs in the pursuit
of our initial Business Combination. We cannot assure you that our plans to raise capital or to complete our initial Business Combination
will be successful.
Recent Developments
On November 7, 2022, NorthView entered into a
Merger Agreement and Plan of Reorganization (the “Merger Agreement”), by and among NorthView, NV Profusa Merger Sub Inc.,
a Delaware corporation and a direct, wholly-owned subsidiary of NorthView (“Merger Sub”), and Profusa, Inc., a California
corporation (“Profusa”).
The Merger Agreement provides that, among other
things, at the closing (the “Closing”) of the transactions contemplated by the Merger Agreement, Merger Sub will merge with
and into Profusa (the “Merger”), with Profusa surviving as a wholly-owned subsidiary of NorthView. In connection with the
Merger, NorthView will change its name to “Profusa, Inc.” The Merger and the other transactions contemplated by the Merger
Agreement are hereinafter referred to as the “Business Combination.”
The Business Combination is subject to customary
closing conditions, including the satisfaction of the minimum available cash condition of $15,000,000, the receipt of certain governmental
approvals and the required approval by the stockholders of NorthView and Profusa. There is no assurance that the Business Combination
will be completed.
The aggregate consideration to be received by
the Profusa stockholders is based on a pre-transaction equity value of $155,000,000. The exchange ratio will be equal to (a) $155,000,000,
divided by an assumed value of NorthView Common Stock of $10.00 per share.
Pursuant to the Merger Agreement, subject to
certain future revenue and stock-price based milestones, Profusa stockholders will have the right to receive an aggregate of up to an
additional 3,875,000 shares of NorthView Common Stock (the “Earnout Shares”). One-quarter of the Earnout Shares will be issued
if, between the 18-month anniversary and the two year anniversary of the Closing, the combined company’s common stock achieves
a daily volume weighted average market price of at least $12.50 per share for any 20 trading days within a 30 consecutive trading day
period (“Milestone Event I”). One-quarter of the Earnout Shares will be issued if, between the first and second anniversary
of the Closing, the combined company’s common stock achieves a daily volume weighted average market price of at least $14.50 per
share for a similar number of days (“Milestone Event II”). Pursuant to the Merger Agreement, the remaining one-quarter of
the Earnout Shares were to be issued if the combined company achieves at least $5,100,000 in revenue in fiscal year 2023, and one-quarter
of the Earnout Shares will be issued if the combined company achieves at least $73,100,000 in revenue in fiscal year 2024, (or up to
one-half of the Earnout Shares if both milestones are achieved). On September 12, 2023, the parties to the Merger Agreement entered into
Amendment No. 1 to the Merger Agreement (the “Amendment”) pursuant to which the parties agreed to revise the revenue earnout
milestones to reflect updated projections provided by Profusa. Specifically, Amendment No. 1 revised the definition of “Milestone
Event III” and “Milestone Event IV” such that one-quarter of the Earnout Shares would be issued to Profusa stockholders
if the combined company achieves Earnout Revenue of $11,864,000 for the fiscal year ended December 31, 2024, and one-quarter of the Earnout
Shares would be issued to Profusa stockholders if the combined company achieves Earnout Revenue of $99,702,000 for the fiscal year ended
December 31, 2025. Amendment No. 1 also clarified the exercise price of certain the Company Warrants.
Additionally, if Milestone Event I or Milestone
Event II are achieved by the second anniversary of the Closing, NorthView’s sponsor, NorthView Sponsor I, LLC and Profusa stockholders,
will be issued additional shares up to the amount of any shares forgone as an inducement to obtaining Additional Financings (as defined
in the Merger Agreement).
Results of Operations
As of September 30, 2023, we had not commenced
any operations. All activity for the period from April 19, 2021 (inception) through September 30, 2023 relates to our formation and the
Initial Public Offering, and, subsequent to the IPO, identifying a target company for a Business Combination. We have neither engaged
in any operations nor generated any operating revenues to date. We will not generate any operating revenues until after the completion
of our initial Business Combination, at the earliest. We will generate non-operating income in the form of interest income and unrealized
gains from the cash and marketable securities held in the Trust Account. We expect to incur expenses as a result of being a public company
(for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses.
For the three months ended September 30, 2023,
we had net loss of $367,345, which consisted of $243,659 for the change in fair value of our warrant liabilities, operating costs of
$290,098, and income tax provision of $25,499, offset by interest income on securities held in the Trust Account of $138,725 and a change
in fair value of convertible note of $53,186. We are required to revalue our liability-classified warrants at the end of each reporting
period and reflect in the unaudited condensed consolidated statements of operations a gain or loss from the change in fair value of the
warrant liabilities in the period in which the change occurred.
For the three months ended September 30, 2022,
we had net income of $1,763,813, which consisted of a gain of $1,074,374 for the change in fair value of our warrant liabilities and
interest income of $1,136,826, offset by formation and operating costs of $404,425 and income tax provision of $42,962. We are required
to revalue our liability-classified warrants at the end of each reporting period and reflect in the unaudited condensed statements of
operations a gain or loss from the change in fair value of the warrant liabilities in the period in which the change occurred.
For the nine months ended September 30, 2023,
we had net income of $925,939, which consisted of interest income on securities held in the Trust Account of $2,103,111 and a gain of
$190,079 for the change in fair value of our warrant liabilities and change in fair value of convertible note of $111,776, offset by
operating costs of $1,048,525, and income tax provision of $430,502. We are required to revalue our liability-classified warrants at
the end of each reporting period and reflect in the unaudited condensed consolidated statements of operations a gain or loss from the
change in fair value of the warrant liabilities in the period in which the change occurred.
For the nine months ended September 30, 2022,
we had net income of $6,685,193, which consisted of a gain of $6,246,897 for the change in fair value of our warrant liabilities and
interest income of $1,371,326, offset by formation and operating costs of $863,546 and income tax provision of $69,484. We are required
to revalue our liability-classified warrants at the end of each reporting period and reflect in the unaudited condensed statements of
operations a gain or loss from the change in fair value of the warrant liabilities in the period in which the change occurred.
Liquidity and Going Concern
As of September 30, 2023, we had $17,342 in cash
and a working capital deficit of $2,846,203.
For the nine months ended September 30, 2023,
cash used in operating activities was $1,719,650. Net income of $925,939 was impacted primarily by trust interest income of $2,103,111,
change in fair value of convertible note of $111,776, change in deferred tax provision of $36,940 and change in fair value of our warrant
liabilities of $190,079. Changes in operating assets and liabilities reflected a use of cash of $203,683 from operating activities during
such period.
For the nine months ended September 30, 2023,
cash provided by investing activities included $340,947 of extension payments made to the trust, $1,171,438 of reimbursement from the
trust of franchise and income tax payments and cash withdrawn from the trust of $184,845,836 in relation to a partial stock redemption.
For the nine months ended September 30, 2023,
cash used in financing activities included $713,015 of proceeds from a convertible promissory note and $184,845,836 of a partial stock
redemption.
For the nine months ended September 30, 2022,
cash used in operating activities was $401,841. Net income of $6,685,193 was impacted primarily by changes in operating assets and liabilities
of $531,189, offset by trust interest income of $1,371,326 and change in fair value of our warrant liabilities of $6,246,897.
For the nine months ended September 30, 2022,
cash provided by investing activities included $8,484 of reimbursement from the trust of franchise tax payments and $25,000 in reimbursement
from a related party.
For the nine months ended September 30, 2022, there was no cash used
in financing activities.
Prior to the completion of the initial public
offering, our liquidity needs had been satisfied through a capital contribution from the sponsor of $25,000 for the founder shares to
cover certain of the offering costs and the loan under an unsecured promissory note from the sponsor of $204,841, which was fully paid
upon the initial public offering. Subsequent to the consummation of the initial public offering and private placement, our liquidity
needs have been satisfied through the proceeds from the consummation of the private placement not held in the trust account, and the
drawdowns on the convertible promissory note.
In order to finance transaction costs in connection
with an intended Business Combination, the initial stockholders or an affiliate of the initial stockholders or certain of the Company’s
officers and directors may, but are not obligated to, provide the Company Working Capital Loans (see Note 5).
On April 27, 2023, the Company signed a Convertible
Working Capital Promissory Note (“the Note”) with the Sponsor for $1,200,000. The Note is non-interest bearing and is due
the earlier of the consummation of a business combination or the date of liquidation. The Sponsor may elect to convert all or any portion
of the unpaid principal balance of this Note into warrants, at a price of $1.00 per warrant. The Company had principal outstanding of
$713,015 and is presenting the Note at fair value on its balance sheet at September 30, 2023 in the amount of $601,239.
The Company has until as late as December 22,
2023 to consummate a Business Combination. It is uncertain that the Company will be able to consummate a Business Combination by December
22, 2023. If a Business Combination is not consummated by the required date, there will be an option to either extend the time available
for us to consummate our initial business combination or execute a mandatory liquidation and subsequent dissolution. In connection with
the Company’s assessment of going concern considerations in accordance with the authoritative guidance in Financial Accounting
Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, “Disclosure of Uncertainties About
an Entity’s Ability to Continue as a Going Concern,” management has determined that mandatory liquidation, and subsequent
dissolution, should the Company be unable to complete a business combination, raises substantial doubt about the Company’s ability
to continue as a going concern for the next twelve months from the issuance of these condensed consolidated financial statements. No
adjustments have been made to the carrying amounts of assets and liabilities should the Company be required to liquidate after December
22, 2023.
Off-Balance Sheet Financing Arrangements
We did not have any off-balance sheet arrangements
as of September 30, 2023 and December 31, 2022.
Contractual Obligations
As of September 30, 2023 and December 31, 2022,
we did not have any long-term debt, capital or operating lease obligations.
We entered into an administrative services agreement
with our sponsor pursuant to which we pay for office space and secretarial and administrative services provided to members of our management
team, in an amount of $5,000 per month. For the nine months ended September 30, 2023, $30,000 had been incurred and billed relating to
the administrative service fee. As of September 30, 2023, $55,000 relating to the administrative service fee was not paid yet and recorded
as due to related party.
NorthView previously engaged I-Bankers as an
advisor to assist in holding meetings to discuss the potential business combination and the target business’ attributes, introduce
NorthView to potential investors that are interested providing funding in connection with a Business Combination, assist NorthView in
obtaining stockholder approval for such business combination and assist NorthView with its press releases and public filings in connection
with such business combination (the “Business Combination Marketing Agreement”). In connection with such engagement, NorthView
agreed to pay IBS a cash fee (the “Business Combination Fee”) for such services upon the consummation of a business combination
in an amount equal to 3.68% of the gross proceeds of its initial public offering (exclusive of any applicable finders’ fees which
might become payable). NorthView had also previously entered into an engagement letter (the “Engagement Letter”) contemplating
the Business Combination Fee. In connection with the Business Combination, NorthView and I-Bankers amended the Business Combination Marketing
Agreement and the Engagement Letter to revise a portion of the Business Combination Fee to be partially payable in NorthView securities
and partially payable in cash upon the closing of the Merger with Profusa, with such securities to be subject to lock-up provisions.
Critical Accounting Policies
Management’s discussion and analysis of
our results of operations and liquidity and capital resources are based on our financial information. We describe our significant accounting
policies in Note 2 – Significant Accounting Policies, of the Notes to Condensed Consolidated Financial Statements included in this
report. Our condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. Certain of our accounting policies
require that management apply significant judgments in defining the appropriate assumptions integral to financial estimates. On an ongoing
basis, management reviews the accounting policies, assumptions, estimates and judgments to ensure that our condensed consolidated financial
statements are presented fairly and in accordance with U.S. GAAP. Judgments are based on historical experience, terms of existing contracts,
industry trends and information available from outside sources, as appropriate. However, by their nature, judgments are subject to an
inherent degree of uncertainty, and, therefore, actual results could differ from our estimates.
Warrant Liabilities
We account for the warrants issued in connection
with the IPO in accordance with the guidance contained in ASC 815-40. Such guidance provides that because the warrants do not meet the
criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, we classified each warrant as a
liability at its fair value. This liability is subject to re-measurement at each balance sheet date. With each such re-measurement,
the warrant liabilities will be adjusted to fair value, with the change in fair value recognized in our unaudited condensed consolidated
statements of operations.
Net (Loss) Income Per Common Stock
We have two categories of shares, which are referred
to as common stock subject to possible redemption and common stock. Earnings and losses are shared pro rata between the two categories
of shares. The 17,404,250 potential shares of common stock for outstanding warrants to purchase our shares were excluded from
diluted earnings per share for the three and nine months ended September 30, 2023 and 2022 because the warrants are contingently exercisable,
and the contingencies have not yet been met. As a result, diluted net (loss) income per share of common stock is the same as basic net
(loss) income per share of common stock for the periods presented.
Common Stock Subject to Possible Redemption
Our common stock sold as part of the Units in
the IPO (“public common stock”) contain a redemption feature which allows for the redemption of such public shares in connection
with our liquidation, or if there is a stockholder vote or tender offer in connection with the initial Business Combination. In accordance
with ASC 480-10-S99, we classify public common stock subject to redemption outside of permanent equity as the redemption provisions are
not solely within our control. The public common stock was issued with other freestanding instruments (i.e., Public Warrants) and as
such, the initial carrying value of public common stock classified as temporary equity was the allocated proceeds determined in accordance
with ASC 470-20.
Recent Accounting Standards
In June 2016, the FASB issued Accounting Standards
Update (“ASU”) 2016-13 – Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on
Financial Instruments (“ASU 2016-13”). This update requires financial assets measured at amortized cost basis to be presented
at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events,
including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported
amount. Since June 2016, the FASB issued clarifying updates to the new standard including changing the effective date for smaller reporting
companies. The guidance is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal
years, with early adoption permitted. The Company adopted ASU 2016-13 on January 1, 2023. The adoption of ASU 2016-13 did not have a
material impact on its financial statements.
Our management does not believe that any other
recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying unaudited
condensed consolidated financial statements.
JOBS Act
The JOBS Act contains provisions that,
among other things, relax certain reporting requirements for qualifying public companies. We qualify as an “emerging growth company”
under the JOBS Act and are allowed to comply with new or revised accounting pronouncements based on the effective date for
private (not publicly traded) companies. We are electing to delay the adoption of new or revised accounting standards, and as a result,
we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for
non-emerging growth companies. As a result, our condensed consolidated financial statements may not be comparable to companies that
comply with new or revised accounting pronouncements as of public company effective dates.
Additionally, we are in the process of evaluating
the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set
forth in the JOBS Act, if, as an “emerging growth company,” we choose to rely on such exemptions we may not be required
to, among other things, (i) provide an independent registered public accounting firm’s attestation report on our system of internal
controls over financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth
public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may
be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the independent registered public accounting firm’s
report providing additional information about the audit and the condensed consolidated financial statements (auditor discussion and analysis),
and (iv) disclose certain executive compensation related items such as the correlation between executive compensation and performance
and comparisons of the CEO’s compensation to median employee compensation. These exemptions will apply for a period of five years
following the completion of our initial public offering or until we are no longer an “emerging growth company,” whichever
is earlier.
Item 3. Quantitative and Qualitative
Disclosures About Market Risk
We are a smaller reporting company as defined
by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.
Item 4. Controls and Procedures Evaluation of Disclosure Controls
and Procedures
Disclosure controls and procedures are designed
to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported
within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our
management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate
to allow timely decisions regarding required disclosure.
Under the supervision and with the participation
of our management, including our principal executive officer and principal financial and accounting officer, we conducted an evaluation
of the effectiveness of our disclosure controls and procedures as of September 30, 2023, as such term is defined in Rules 13a-15(e) and
15d-15(e) under the Exchange Act. Based upon their evaluation, our principal executive officer and principal financial and accounting
officer, concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were
effective as of September 30, 2023.
We do not expect that our disclosure controls
and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and
operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met.
Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits
must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation
of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances
of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of
future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control
over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent fiscal
quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II - OTHER INFORMATION
Item 1. Legal Proceedings.
None.
Item 1A. Risk Factors.
Factors that could cause our actual results to
differ materially from those in this report include the risk factors described in our Form 10-K for the fiscal year ended December 31,
2022. As of the date of this Report, except as set forth below, there have been no material changes to the risk factors disclosed in
our Form 10-K for the year ended December 31, 2022 and in our Form 10-Q for the quarters ended March 31, 2023 and June 30, 2023 filed
with the SEC.
We may not be
able to complete the Business Combination pursuant to the Merger Agreement. If we are unable to do so, we will incur substantial costs
associated with withdrawing from the transaction and may not be able to find additional sources of financing to cover those costs.
In connection with the
Merger Agreement, we have incurred substantial costs researching, planning and negotiating the transaction. These costs include, but
are not limited to, costs associated with securing sources of financing, costs associated with employing and retaining third-party advisors
who performed the financial, auditing and legal services required to complete the transaction, and the expenses generated by our officers,
executives, and employees in connection with the transaction. If, for whatever reason, the transactions contemplated by the Merger Agreement
fail to close, we will be responsible for these costs, but will have no source of revenue with which to pay them. We may need to obtain
additional sources of financing in order to meet our obligations, which we may not be able to secure on the same terms as our existing
financing or at all. If we are unable to secure new sources of financing and do not have sufficient funds to meet our obligations, we
will be forced to cease operations and liquidate the trust account.
If we are deemed
to be an investment company for purposes of the Investment Company Act of 1940, as amended (the “Investment Company Act”),
we would be required to institute burdensome compliance requirements and our activities would be severely restricted and, as a result,
we may abandon our efforts to consummate an initial business combination and liquidate.
There is currently uncertainty
concerning the applicability of the Investment Company Act to blank check companies, or SPACs, including companies like ours. As a result,
it is possible that a claim could be made that we have been operating as an unregistered investment company.
If we are deemed to
be an investment company under the Investment Company Act, our activities would be severely restricted. In addition, we would be subject
to burdensome compliance requirements. We do not believe that our principal activities will subject us to regulation as an investment
company under the Investment Company Act. However, if we are deemed to be an investment company and subject to compliance with and regulation
under the Investment Company Act, we would be subject to additional regulatory burdens and expenses for which we have not allotted funds.
As a result, unless we are able to modify our activities so that we would not be deemed an investment company, we would expect to abandon
our efforts to complete an initial business combination and instead to liquidate. If we were to liquidate, our warrants and rights will
expire worthless. This will also cause you to lose the investment opportunity in connection with the Business Combination and any other
target company, and the chance of realizing future gains on your investment through any price appreciation in the combined company.
We may not be
able to complete an initial business combination with a U.S. target company if such initial business combination is subject to U.S. foreign
investment regulations and review by a U.S. government entity such as the Committee on Foreign Investment in the United States (CFIUS),
or is ultimately prohibited.
None of the members
of the Company’s sponsor group is, is controlled by, or has substantial ties with a foreign person and therefore, we believe, will
not be subject to U.S. foreign investment regulations and review by a U.S. government entity such as the Committee on Foreign Investment
in the United States (CFIUS). However, our initial business combination with a U.S. business may be subject to CFIUS review, the scope
of which was expanded by the Foreign Investment Risk Review Modernization Act of 2018 (“FIRRMA”), to include certain non-passive,
non-controlling investments in sensitive U.S. businesses and certain acquisitions of real estate even with no underlying U.S. business.
FIRRMA, and subsequent implementing regulations that are now in force, also subjects certain categories of investments to mandatory filings.
If our potential initial business combination with a U.S. business falls within CFIUS’s jurisdiction, we may determine that we
are required to make a mandatory filing or that we will submit a voluntary notice to CFIUS, or to proceed with the initial business combination
without notifying CFIUS and risk CFIUS intervention, before or after closing the initial business combination. CFIUS may decide to block
or delay our initial business combination, impose conditions to mitigate national security concerns with respect to such initial business
combination or order us to divest all or a portion of a U.S. business of the combined company without first obtaining CFIUS clearance,
which may limit the attractiveness of or prevent us from pursuing certain initial business combination opportunities that we believe
would otherwise be beneficial to us and our shareholders. As a result, the pool of potential targets with which we could complete an
initial business combination may be limited and we may be adversely affected in terms of competing with other special purpose acquisition
companies which do not have similar foreign ownership issues.
Moreover, the process
of government review, whether by the CFIUS or otherwise, could be lengthy and we have limited time to complete our initial business combination.
If we cannot complete our initial business combination within the time period as required by our certificate of incorporation because
the review process extends beyond such timeframe or because our initial business combination is ultimately prohibited by CFIUS or another
U.S. government entity, we may be required to liquidate. If we liquidate, our public shareholders may only receive their pro rata portion
of the Trust Account, and our warrants and rights will expire worthless. This will also cause you to lose the investment opportunity
in a target company, and the chance of realizing future gains on your investment through any price appreciation in the combined company.
A new 1% U.S.
federal excise tax could be imposed on us in connection with redemptions.
On August 16, 2022,
the Inflation Reduction Act of 2022 (the “IRA”) was signed into federal law. The IRA provides for, among other things, a
new U.S. federal 1% excise tax on certain repurchases (including redemptions) of stock by publicly traded U.S. corporations, by certain
U.S. subsidiaries of publicly traded non-U.S. corporations, by “covered surrogate foreign corporations” (as defined in the
IRA) and by certain affiliates of the foregoing (each, a “covered corporation”). Because our securities are trading on the
Nasdaq, we are a “covered corporation” for this purpose. The excise tax is imposed on the repurchasing corporation itself,
not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the
shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are
permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same
taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of Treasury has been given authority to provide
regulations and other guidance to carry out, and to prevent the avoidance of the excise tax. The IRA applies only to repurchases that
occur after December 31, 2022.
If we complete a business
combination after December 31, 2022, any redemption or other repurchase that occurs in connection with the business combination, or any
other redemption or other repurchase that occurs after December 31, 2022 may be subject to the excise tax. Whether and to what extent
we would be subject to the excise tax would depend on a number of factors, including (i) the fair market value of the redemptions and
repurchases, (ii) the nature and amount of the equity issued in connection with the business combination (or otherwise issued not in
connection with the business combination but issued within the same taxable year of the business combination), and (iii) the content
of regulations and other guidance from the U.S. Department of the Treasury. In addition, because the excise tax would be payable by us,
and not by the redeeming holder, the mechanics of any required payment of the excise tax have not been determined. The foregoing could
cause a reduction in the cash available on hand to complete any business combination and in our ability to complete any such business
combination.
On March 22, 2023, the
Company’s stockholders redeemed 18,000,868 shares for a total of $184,845,836. The Company determined that a liability for excise
tax should be recorded due to the redeemed shares. As of September 30, 2023, the Company recorded a charge to stockholders’ deficit
of $1,848,455 of excise tax liability calculated as 1% of shares redeemed.
Item 2. Unregistered Sales of Equity Securities and Use of
Proceeds.
On December 22, 2021, we consummated our Initial
Public Offering of 18,975,000 Units, which included 2,475,000 Units issued pursuant to the full exercise of the over-allotment option
granted to the underwriters, generating gross proceeds of $189,750,000. I-Bankers Securities, Inc. and Dawson James Securities, Inc.
acted as joint book-running managers of the Initial Public Offering. The securities in the offering were registered under the Securities
Act on registration statements on Form S-1 (Nos. 333-257156 and 333-261763). The Securities and Exchange Commission declared
the registration statement effective on December 20, 2021.
Simultaneous with the consummation of the Initial
Public Offering, we consummated the private placement of an aggregate of 7,347,500 Private Placement Warrants to the Sponsor and I-Bankers
and Dawson James at a price of $1.00 per Private Placement Warrant, generating total proceeds of $7,347,500.
The Private Placement Warrants are identical
to the Warrants sold in the IPO except that the Private Placement Warrants: (i) are not redeemable by the Company and (ii) may be exercised
for cash or on a cashless basis, in each case so long as they are held by the initial purchasers or any of their permitted transferees.
We paid a total of $3,450,000 in underwriting
discounts and commissions and $609,623 for other costs and expenses related to the IPO. I-Bankers and Dawson James, representatives of
the several underwriters in the IPO, received a portion of the underwriting discounts and commissions related to the IPO. We also repaid
the promissory note to the Sponsor from the proceeds of the IPO. After deducting the underwriting discounts and commissions and incurred
offering costs, the total net proceeds from our IPO and the sale of the private placement warrants was $193,037,877, of which $191,647,500
(or $10.10 per unit sold in the IPO) was placed in the trust account. Other than as described above, no payments were made by us to directors,
officers or persons owning ten percent or more of our common stock or to their associates, or to our affiliates.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not Applicable.
Item 5. Other Information.
During the period covered by this Quarterly Report,
none of the Company’s directors or executive officers has adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule
10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).
Item 6. Exhibits
The following exhibits are filed as part of,
or incorporated by reference into, this Quarterly Report on Form 10-Q.
No. |
|
Description
of Exhibit |
2.1+ |
|
Merger Agreement and Plan of Reorganization, dated as of November 7, 2022, by and among NorthView, NV Profusa Merger Sub, Inc. and Profusa, Inc. (incorporated by reference to Exhibit 2.1 to NorthView’s Current Report on Form 8-K, filed with the SEC on November 10, 2022).) |
|
|
|
2.2 |
|
Amendment No. 1 to Merger Agreement, dated September 12, 2023, by and among NorthView, Profusa and Merger Sub (incorporated by reference to Exhibit 2.2 to NorthView’s Current Report on Form 8-K, filed with the SEC on September 13, 2023) |
|
|
|
31.1* |
|
Certification
of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002 |
|
|
31.2* |
|
Certification
of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002 |
|
|
32.1* |
|
Certification
of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes—
Oxley Act of 2002 |
|
|
32.2* |
|
Certification
of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002 |
|
|
101.INS |
|
Inline
XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within
the Inline XBRL document) |
|
|
101.SCH |
|
Inline
XBRL Taxonomy Extension Schema Document |
|
|
101.CAL |
|
Inline
XBRL Taxonomy Extension Calculation Linkbase Document |
|
|
101.DEF |
|
Inline
XBRL Taxonomy Extension Definition Linkbase Document |
|
|
101.LAB |
|
Inline
XBRL Taxonomy Extension Labels Linkbase Document |
|
|
101.PRE |
|
Inline
XBRL Taxonomy Extension Presentation Linkbase Document |
|
|
104 |
|
Cover
Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
* |
These
certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference
in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing. |
+ |
Certain
of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2). The Registrant
agrees to furnish supplementally a copy of all omitted exhibits and schedules to the SEC upon its request. |
SIGNATURES
In accordance with the requirements of the Exchange
Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
NORTHVIEW
ACQUISITION CORP. |
|
|
|
Date: November 20,
2023 |
By: |
/s/
Jack Stover |
|
Name: |
Jack Stover |
|
Title: |
Chief Executive Officer |
|
|
|
|
By: |
/s/
Fred Knechtel |
|
Name: |
Fred Knechtel |
|
Title: |
Chief Financial Officer |
31
18975000
18975000
8830864
974132
0.05
0.09
0.14
0.20
5193750
5193750
5193750
5193750
0.05
0.09
0.14
0.20
0.05
0.05
0.09
0.09
0.14
0.14
0.20
0.20
false
--12-31
Q3
0001859807
0001859807
2023-01-01
2023-09-30
0001859807
nvac:CommonStock00001ParValuePerShareMember
2023-01-01
2023-09-30
0001859807
nvac:RightsEachRightConvertibleIntoOnetenthOfOneShareOfCommonStockMember
2023-01-01
2023-09-30
0001859807
nvac:WarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtAnExercisePriceOf1150PerWholeShareMember
2023-01-01
2023-09-30
0001859807
2023-11-20
0001859807
2023-09-30
0001859807
2022-12-31
0001859807
us-gaap:RelatedPartyMember
2023-09-30
0001859807
us-gaap:RelatedPartyMember
2022-12-31
0001859807
2023-07-01
2023-09-30
0001859807
2022-07-01
2022-09-30
0001859807
2022-01-01
2022-09-30
0001859807
nvac:CommonStockSubjectToPossibleRedemptionMember
2023-07-01
2023-09-30
0001859807
nvac:CommonStockSubjectToPossibleRedemptionMember
2022-07-01
2022-09-30
0001859807
nvac:CommonStockSubjectToPossibleRedemptionMember
2023-01-01
2023-09-30
0001859807
nvac:CommonStockSubjectToPossibleRedemptionMember
2022-01-01
2022-09-30
0001859807
us-gaap:CommonStockMember
2022-12-31
0001859807
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001859807
us-gaap:RetainedEarningsMember
2022-12-31
0001859807
us-gaap:CommonStockMember
2023-01-01
2023-03-31
0001859807
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-03-31
0001859807
us-gaap:RetainedEarningsMember
2023-01-01
2023-03-31
0001859807
2023-01-01
2023-03-31
0001859807
us-gaap:CommonStockMember
2023-03-31
0001859807
us-gaap:AdditionalPaidInCapitalMember
2023-03-31
0001859807
us-gaap:RetainedEarningsMember
2023-03-31
0001859807
2023-03-31
0001859807
us-gaap:CommonStockMember
2023-04-01
2023-06-30
0001859807
us-gaap:AdditionalPaidInCapitalMember
2023-04-01
2023-06-30
0001859807
us-gaap:RetainedEarningsMember
2023-04-01
2023-06-30
0001859807
2023-04-01
2023-06-30
0001859807
us-gaap:CommonStockMember
2023-06-30
0001859807
us-gaap:AdditionalPaidInCapitalMember
2023-06-30
0001859807
us-gaap:RetainedEarningsMember
2023-06-30
0001859807
2023-06-30
0001859807
us-gaap:CommonStockMember
2023-07-01
2023-09-30
0001859807
us-gaap:AdditionalPaidInCapitalMember
2023-07-01
2023-09-30
0001859807
us-gaap:RetainedEarningsMember
2023-07-01
2023-09-30
0001859807
us-gaap:CommonStockMember
2023-09-30
0001859807
us-gaap:AdditionalPaidInCapitalMember
2023-09-30
0001859807
us-gaap:RetainedEarningsMember
2023-09-30
0001859807
us-gaap:CommonStockMember
2021-12-31
0001859807
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0001859807
us-gaap:RetainedEarningsMember
2021-12-31
0001859807
2021-12-31
0001859807
us-gaap:CommonStockMember
2022-01-01
2022-03-31
0001859807
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-03-31
0001859807
us-gaap:RetainedEarningsMember
2022-01-01
2022-03-31
0001859807
2022-01-01
2022-03-31
0001859807
us-gaap:CommonStockMember
2022-03-31
0001859807
us-gaap:AdditionalPaidInCapitalMember
2022-03-31
0001859807
us-gaap:RetainedEarningsMember
2022-03-31
0001859807
2022-03-31
0001859807
us-gaap:CommonStockMember
2022-04-01
2022-06-30
0001859807
us-gaap:AdditionalPaidInCapitalMember
2022-04-01
2022-06-30
0001859807
us-gaap:RetainedEarningsMember
2022-04-01
2022-06-30
0001859807
2022-04-01
2022-06-30
0001859807
us-gaap:CommonStockMember
2022-06-30
0001859807
us-gaap:AdditionalPaidInCapitalMember
2022-06-30
0001859807
us-gaap:RetainedEarningsMember
2022-06-30
0001859807
2022-06-30
0001859807
us-gaap:CommonStockMember
2022-07-01
2022-09-30
0001859807
us-gaap:AdditionalPaidInCapitalMember
2022-07-01
2022-09-30
0001859807
us-gaap:RetainedEarningsMember
2022-07-01
2022-09-30
0001859807
us-gaap:CommonStockMember
2022-09-30
0001859807
us-gaap:AdditionalPaidInCapitalMember
2022-09-30
0001859807
us-gaap:RetainedEarningsMember
2022-09-30
0001859807
2022-09-30
0001859807
us-gaap:IPOMember
2021-12-22
0001859807
us-gaap:OverAllotmentOptionMember
2021-12-22
0001859807
us-gaap:CommonStockMember
2021-12-22
0001859807
2021-12-22
0001859807
2021-12-22
2021-12-22
0001859807
us-gaap:PrivatePlacementMember
2023-09-30
0001859807
us-gaap:OverAllotmentOptionMember
2023-09-30
0001859807
us-gaap:PrivatePlacementMember
2023-01-01
2023-09-30
0001859807
nvac:BusinessCombinationMember
2023-09-30
0001859807
us-gaap:IPOMember
2021-12-22
2021-12-22
0001859807
us-gaap:IPOMember
2021-12-31
2021-12-31
0001859807
nvac:SponsorMember
2023-09-30
0001859807
2023-04-27
0001859807
2023-04-27
2023-04-27
0001859807
2023-03-10
2023-03-10
0001859807
us-gaap:CommonStockMember
2023-03-22
0001859807
2023-03-22
0001859807
nvac:USFederalMember
2022-08-16
2022-08-16
0001859807
2022-08-16
2022-08-16
0001859807
2023-03-22
2023-03-22
0001859807
nvac:USTreasuryBillsHeldInTrustAccountMember
2023-01-01
2023-09-30
0001859807
nvac:TrustAccountMember
2022-06-29
2022-06-29
0001859807
nvac:PublicWarrantMember
2023-01-01
2023-09-30
0001859807
us-gaap:OverAllotmentOptionMember
2023-01-01
2023-09-30
0001859807
us-gaap:CashMember
2022-12-31
0001859807
us-gaap:CashMember
2022-01-01
2022-12-31
0001859807
us-gaap:USTreasurySecuritiesMember
2022-12-31
0001859807
us-gaap:USTreasurySecuritiesMember
2022-01-01
2022-12-31
0001859807
2022-01-01
2022-12-31
0001859807
us-gaap:CommonStockMember
2023-01-01
2023-09-30
0001859807
us-gaap:CommonStockMember
2022-01-01
2022-09-30
0001859807
us-gaap:IPOMember
2022-12-22
2022-12-22
0001859807
us-gaap:OverAllotmentOptionMember
2022-12-22
2022-12-22
0001859807
us-gaap:IPOMember
2022-12-22
0001859807
us-gaap:CommonStockMember
2022-12-22
0001859807
us-gaap:WarrantMember
2022-12-22
0001859807
nvac:PublicWarrantsMember
2023-01-01
2023-09-30
0001859807
srt:MinimumMember
2023-01-01
2023-09-30
0001859807
srt:MaximumMember
2023-01-01
2023-09-30
0001859807
nvac:IBankersAndDawsonJamesMember
us-gaap:PrivatePlacementMember
2023-09-30
0001859807
nvac:IBankersAndDawsonJamesMember
nvac:SponsorMember
2023-09-30
0001859807
2021-04-01
2021-04-30
0001859807
2021-04-30
0001859807
us-gaap:CommonStockMember
2021-04-30
0001859807
2021-10-01
2021-10-31
0001859807
2021-04-19
0001859807
2021-11-05
0001859807
2022-06-15
2022-06-15
0001859807
us-gaap:IPOMember
2023-01-01
2023-09-30
0001859807
us-gaap:IPOMember
2022-01-01
2022-12-31
0001859807
us-gaap:OverAllotmentOptionMember
2021-12-22
2021-12-22
0001859807
nvac:BankersAndDawsonJamesMember
2021-12-22
0001859807
nvac:BankersAndDawsonJamesMember
2023-01-01
2023-09-30
0001859807
us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember
2023-09-30
0001859807
srt:ScenarioForecastMember
2024-01-01
2024-12-31
0001859807
srt:ScenarioForecastMember
2025-01-01
2025-12-31
0001859807
nvac:MonteCarloSimulationMember
2023-01-01
2023-09-30
0001859807
nvac:MonteCarloSimulationMember
2023-09-30
0001859807
2021-12-20
2021-12-20
0001859807
nvac:CashAndMarketableSecuritiesHeldInTrustMember
2023-09-30
0001859807
nvac:CashAndMarketableSecuritiesHeldInTrustMember
us-gaap:FairValueInputsLevel1Member
2023-09-30
0001859807
nvac:CashAndMarketableSecuritiesHeldInTrustMember
us-gaap:FairValueInputsLevel2Member
2023-09-30
0001859807
nvac:CashAndMarketableSecuritiesHeldInTrustMember
us-gaap:FairValueInputsLevel3Member
2023-09-30
0001859807
nvac:PublicWarrantsMember
2023-01-01
2023-09-30
0001859807
nvac:PublicWarrantsMember
us-gaap:FairValueInputsLevel1Member
2023-01-01
2023-09-30
0001859807
nvac:PublicWarrantsMember
us-gaap:FairValueInputsLevel2Member
2023-01-01
2023-09-30
0001859807
nvac:PublicWarrantsMember
us-gaap:FairValueInputsLevel3Member
2023-01-01
2023-09-30
0001859807
nvac:PrivatePlacementWarrantsMember
2023-01-01
2023-09-30
0001859807
nvac:PrivatePlacementWarrantsMember
us-gaap:FairValueInputsLevel1Member
2023-01-01
2023-09-30
0001859807
nvac:PrivatePlacementWarrantsMember
us-gaap:FairValueInputsLevel2Member
2023-01-01
2023-09-30
0001859807
nvac:PrivatePlacementWarrantsMember
us-gaap:FairValueInputsLevel3Member
2023-01-01
2023-09-30
0001859807
nvac:RepresentativesWarrantsMember
2023-01-01
2023-09-30
0001859807
nvac:RepresentativesWarrantsMember
us-gaap:FairValueInputsLevel1Member
2023-01-01
2023-09-30
0001859807
nvac:RepresentativesWarrantsMember
us-gaap:FairValueInputsLevel2Member
2023-01-01
2023-09-30
0001859807
nvac:RepresentativesWarrantsMember
us-gaap:FairValueInputsLevel3Member
2023-01-01
2023-09-30
0001859807
us-gaap:FairValueInputsLevel1Member
2023-09-30
0001859807
us-gaap:FairValueInputsLevel2Member
2023-09-30
0001859807
us-gaap:FairValueInputsLevel3Member
2023-09-30
0001859807
nvac:PublicWarrantsMember
2022-01-01
2022-12-31
0001859807
nvac:PublicWarrantsMember
us-gaap:FairValueInputsLevel1Member
2022-01-01
2022-12-31
0001859807
nvac:PublicWarrantsMember
us-gaap:FairValueInputsLevel2Member
2022-01-01
2022-12-31
0001859807
nvac:PublicWarrantsMember
us-gaap:FairValueInputsLevel3Member
2022-01-01
2022-12-31
0001859807
nvac:PrivatePlacementWarrantsMember
2022-01-01
2022-12-31
0001859807
nvac:PrivatePlacementWarrantsMember
us-gaap:FairValueInputsLevel1Member
2022-01-01
2022-12-31
0001859807
nvac:PrivatePlacementWarrantsMember
us-gaap:FairValueInputsLevel2Member
2022-01-01
2022-12-31
0001859807
nvac:PrivatePlacementWarrantsMember
us-gaap:FairValueInputsLevel3Member
2022-01-01
2022-12-31
0001859807
nvac:RepresentativesWarrantsMember
2022-01-01
2022-12-31
0001859807
nvac:RepresentativesWarrantsMember
us-gaap:FairValueInputsLevel1Member
2022-01-01
2022-12-31
0001859807
nvac:RepresentativesWarrantsMember
us-gaap:FairValueInputsLevel2Member
2022-01-01
2022-12-31
0001859807
nvac:RepresentativesWarrantsMember
us-gaap:FairValueInputsLevel3Member
2022-01-01
2022-12-31
0001859807
nvac:RepresentativesWarrantsMember
2022-12-31
0001859807
nvac:RepresentativesWarrantsMember
us-gaap:FairValueInputsLevel1Member
2022-12-31
0001859807
nvac:RepresentativesWarrantsMember
us-gaap:FairValueInputsLevel2Member
2022-12-31
0001859807
nvac:RepresentativesWarrantsMember
us-gaap:FairValueInputsLevel3Member
2022-12-31
0001859807
nvac:PrivatePlacementWarrantsMember
2022-12-31
0001859807
nvac:PublicWarrantsMember
2022-12-31
0001859807
naics:ZZ541840
2022-12-31
0001859807
nvac:WarrantLiabilityMember
2022-12-31
0001859807
nvac:PrivatePlacementWarrantsMember
2023-01-01
2023-03-31
0001859807
nvac:PublicWarrantsMember
2023-01-01
2023-03-31
0001859807
naics:ZZ541840
2023-01-01
2023-03-31
0001859807
nvac:WarrantLiabilityMember
2023-01-01
2023-03-31
0001859807
nvac:PrivatePlacementWarrantsMember
2023-03-31
0001859807
nvac:PublicWarrantsMember
2023-03-31
0001859807
naics:ZZ541840
2023-03-31
0001859807
nvac:WarrantLiabilityMember
2023-03-31
0001859807
nvac:PrivatePlacementWarrantsMember
2023-04-01
2023-06-30
0001859807
nvac:PublicWarrantsMember
2023-04-01
2023-06-30
0001859807
naics:ZZ541840
2023-04-01
2023-06-30
0001859807
nvac:WarrantLiabilityMember
2023-04-01
2023-06-30
0001859807
nvac:PrivatePlacementWarrantsMember
2023-06-30
0001859807
nvac:PublicWarrantsMember
2023-06-30
0001859807
naics:ZZ541840
2023-06-30
0001859807
nvac:WarrantLiabilityMember
2023-06-30
0001859807
nvac:PrivatePlacementWarrantsMember
2023-07-01
2023-09-30
0001859807
nvac:PublicWarrantsMember
2023-07-01
2023-09-30
0001859807
naics:ZZ541840
2023-07-01
2023-09-30
0001859807
nvac:WarrantLiabilityMember
2023-07-01
2023-09-30
0001859807
nvac:PrivatePlacementWarrantsMember
2023-09-30
0001859807
nvac:PublicWarrantsMember
2023-09-30
0001859807
naics:ZZ541840
2023-09-30
0001859807
nvac:WarrantLiabilityMember
2023-09-30
0001859807
nvac:PrivatePlacementWarrantsMember
2021-12-31
0001859807
nvac:PublicWarrantsMember
2021-12-31
0001859807
naics:ZZ541840
2021-12-31
0001859807
nvac:WarrantLiabilityMember
2021-12-31
0001859807
nvac:PrivatePlacementWarrantsMember
2022-01-01
2022-03-31
0001859807
nvac:PublicWarrantsMember
2022-01-01
2022-03-31
0001859807
naics:ZZ541840
2022-01-01
2022-03-31
0001859807
nvac:WarrantLiabilityMember
2022-01-01
2022-03-31
0001859807
nvac:PrivatePlacementWarrantsMember
2022-03-31
0001859807
nvac:PublicWarrantsMember
2022-03-31
0001859807
naics:ZZ541840
2022-03-31
0001859807
nvac:WarrantLiabilityMember
2022-03-31
0001859807
nvac:PrivatePlacementWarrantsMember
2022-04-01
2022-06-30
0001859807
nvac:PublicWarrantsMember
2022-04-01
2022-06-30
0001859807
naics:ZZ541840
2022-04-01
2022-06-30
0001859807
nvac:WarrantLiabilityMember
2022-04-01
2022-06-30
0001859807
nvac:PrivatePlacementWarrantsMember
2022-06-30
0001859807
nvac:PublicWarrantsMember
2022-06-30
0001859807
naics:ZZ541840
2022-06-30
0001859807
nvac:WarrantLiabilityMember
2022-06-30
0001859807
nvac:PrivatePlacementWarrantsMember
2022-07-01
2022-09-30
0001859807
nvac:PublicWarrantsMember
2022-07-01
2022-09-30
0001859807
naics:ZZ541840
2022-07-01
2022-09-30
0001859807
nvac:WarrantLiabilityMember
2022-07-01
2022-09-30
0001859807
nvac:PrivatePlacementWarrantsMember
2022-09-30
0001859807
nvac:PublicWarrantsMember
2022-09-30
0001859807
naics:ZZ541840
2022-09-30
0001859807
nvac:WarrantLiabilityMember
2022-09-30
xbrli:shares
iso4217:USD
iso4217:USD
xbrli:shares
xbrli:pure
1. I have reviewed this
Quarterly Report on Form 10-Q of NorthView Acquisition Corp.;
2. Based on my knowledge,
this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. Based on my knowledge,
the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s
other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
a. Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;
b. Designed such internal
control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness
of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report
any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s
other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to
the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent
functions):
a. All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant’s ability to record, process, summarize and report financial information; and
b. Any fraud, whether or
not material, that involves management or other employees who have a significant role in the registrant’s internal controls over
financial reporting.
1. I have reviewed this
Quarterly Report on Form 10-Q of NorthView Acquisition Corp.;
2. Based on my knowledge,
this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. Based on my knowledge,
the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s
other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
a. Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;
b. Designed such internal
control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness
of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report
any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s
other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to
the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent
functions):
a. All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant’s ability to record, process, summarize and report financial information; and
b. Any fraud, whether or
not material, that involves management or other employees who have a significant role in the registrant’s internal controls over
financial reporting.
In connection with the
Quarterly Report of NorthView Acquisition Corp. (the “Company”) on Form 10-Q for the quarter ended
September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jack
Stover, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
In connection with the
Quarterly Report of NorthView Acquisition Corp. (the “Company”) on Form 10-Q for the quarter ended
September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Fred
Knechtel, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: